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Abstract 
Objectives: Chronic pain is a condition pharmacists frequently encounter in practice; 
however, the pharmacist’s role in the management of chronic pain is under-investigated.  
This study examines pharmacist perceptions and experiences in providing care to patients 
with chronic pain in the community setting.  
Methods: Practicing primary care pharmacists in Ontario were recruited and interviewed 
using a semi-structured guide. Interviews were analyzed using modified grounded theory. 
Sample recruitment continued until saturation was achieved. 
Results: Twelve pharmacists responded to the email invitation. Two did not meet eligibility 
criteria and one withdrew.  The sample consisted of 6 female and 3 male pharmacists with 
a mean age of 47 years (range: 27 – 63) and mean of 20 years (range: 2 – 40) of practice.  
Five themes emerged from the content analysis: (1) perception of chronic pain (2) concern 
about opioid use (3) lack of support for patients, (4) communication with prescribers, and 
(5) knowledge gaps. 
Participants were comfortable with their knowledge of chronic pain and were empathetic 
of their patients’ suffering. They also felt their role is limited within the current healthcare 
system.  Participants reported that misuse of opioids is the most challenging; issues 
included high potential for misuse, inadequate monitoring and under-use of other 
medications and resources for the treatment of chronic pain. Additionally, participants 
believed that patients suffer from lack of support by their family, employers and the health 
care system. Furthermore, trust was identified as the most important parameter in 
building a collaborative relationship with physicians. Finally, participants felt more training 
on legal issues related to opioids is required. 
iv 
 
Conclusion: Pharmacists were empathetic towards patients with chronic pain; however, 
they felt their role is limited in current climate. Deficiencies in the current system of 
managing chronic pain were identified including opioid use as the most challenging. Future 
research should investigate expansion of pharmacist roles to optimize chronic pain 
management.   
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Introduction 
1. Definition of chronic pain 
Pain is an unpleasant distressful sensation in a particular part of body usually following 
tissue damage. Pain prompts the individual to avoid further exposure to damaging situations 
and to protect the damaged part (1). Everybody experiences pain in their life; however, 
developing an adequate definition is difficult due to the fact that pain is a subjective 
phenomenon. The International Association for the Study of Pain (IASP) (2) defines pain 
as “an unpleasant sensory and emotional experience associated with actual or potential 
tissue damage.” 
Pain is usually transitory, lasting until the stimulus is removed or the underlying damage or 
pathological condition has healed, but sometimes it lasts for a longer time and may even 
persist for years. Acute pain resolves quickly, but long-lasting pain is called chronic pain. 
The IASP (2) defines chronic pain as "pain that persists beyond normal tissue healing time.” 
In terms of time interval, chronic pain is commonly defined as a pain duration of greater 
than 3 months (3). Chronic pain may have nociceptive, neuropathic, or mixed etiology. 
Nociceptive pain is caused by the detection of potentially harmful stimuli by the pain 
receptors around the body while neuropathic pain is associated with damage to the neurons 
in the body. Chronic pain is a major public health concern as it affects general health, quality 
of life, social and economic well-being (4). 
2. Prevalence 
Due to differences in populations and modes of data collection, estimates of the prevalence 
of chronic pain are highly variable, with estimates ranging from 2%-55% (3). Some studies 
have estimated that 80% of adults have experienced low back pain at some point during 
their lifetime (5, 6). In a large survey of chronic pain in 15 European countries, 19% of the 
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study population had suffered from pain for more than six months, had experienced pain 
within the last month, and several times during the last week, with a last episode pain 
intensity score exceeding five out of ten in a numeric rating scale (7). 
Chronic pain is also a common health complaint among Canadian adults (8). The prevalence 
of nonspecific chronic pain is estimated at 17% (9). It is more common among older adults 
and more prevalent among females compared to males. Nearly half of chronic pain patients 
reported suffering from chronic pain for more than 10 years and one-third reported very 
severe pain intensity (8). 
Back pain, headaches, and diabetic neuropathy are among the most common types of pain 
reported (7). In a study of a Canadian population, 84% of participants had experienced back 
pain during their lifetime. Among this study population, 12.3% had experienced high-
intensity/low-disability low back pain and 10.7% had experienced high-intensity/high-
disability low back pain during the last six months of the study (5). In addition to back pain, 
three to five percent of the population reported daily headaches (10, 11) and 20 to 30% of 
diabetic patients suffer from diabetic neuropathy (12, 13). 
3. Treatments for chronic pain 
3.1 Pharmacologic treatments - Non-opioid medications 
Non-opioid medications consist of non-steroidal anti-inflammatory drugs (NSAIDs), 
acetaminophen, antidepressants, anticonvulsants, and topical analgesics. The efficacy of 
NSAIDs has been well-established for several pain disorders such as osteoarthritis, 
rheumatoid arthritis, and back pain (14); however, NSAIDs have little value in neuropathic 
pain (15). The use of NSAIDs are complicated by cardiovascular and gastrointestinal side 
effects. Cardiovascular effects are especially significant in patients with hypertension and 
coronary diseases. Naproxen is considered the safest among NSAIDs in hypertensive 
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patients, while selective cyclooxygenase (COX-2) inhibitors such as celecoxib have fewer 
gastrointestinal side effects, but are associated with higher cardiovascular risk (14).  
Antidepressants include tricyclic antidepressants (TCAs), selective serotonin reuptake 
inhibitors (SSRIs), and selective serotonin and noradrenaline reuptake inhibitors (SNRIs). 
This group is most effective for neuropathic pain, fibromyalgia, headaches, and back-pain 
(16, 17). TCAs such as amitriptyline and imipramine inhibit reuptake of serotonin and 
norepinephrine. While they have a long history of application for management of chronic 
pain, they are less tolerable and less safe especially for elderly patients due to sedation and 
important safety concerns such as hypotension and arrhythmias. SSRIs specifically block 
serotonin reuptake without additional blockade of other receptors, so they have fewer 
adverse effects than TCAs. There are reports of the effectiveness of SSRIs in treating 
chronic pain, but they are considered to be less consistent than TCAs (18). Duloxetine has 
been approved for neuropathic pain and fibromyalgia and its efficacy for diabetic 
neuropathy has been demonstrated (19, 20). 
Among anticonvulsants, gabapentin, pregabalin, and carbamazepine are more successful in 
treating chronic non-cancer pain (17). Carbamazepine alleviates pain by decreasing 
conductance in Na+ channels and inhibiting ectopic discharges (21). Pregabalin is approved 
for the treatment of neuropathic pain and fibromyalgia (22), while lamotrigine has shown to 
be effective in treating trigeminal neuralgia and diabetic neuropathy (23, 24). Pregabalin 
reduce the pain by inhibitory action on Ca+ channels (21, 25) while Lamotrigine reduces the 
pain related transmission signals by enhancing the action of and decreasing conductance in 
Na+ Channels (21, 25).  
Topical agents are recommended for localized non-cancer chronic pain and consequently 
have the advantage of avoiding systemic adverse effects. Capsaicin is efficacious in treating 
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neuropathic pain and osteoarthritis (26). Topical lidocaine is useful for the treatment of 
peripheral localized neuropathic pain. 
3.2 Pharmacologic treatments - Opioid medications 
Opioids such as morphine, methadone, tramadol demonstrate significant pain reduction in 
patients with nociceptive and/or neuropathic pain (27, 28). However, data regarding long 
term (more than six months) use of opioids in chronic pain management is inconsistent (29, 
30). Although opioids can be effective in pain reduction, there are significant concerns 
regarding the safety and misuse of these medications. Barriers to the optimal prescribing of 
opioids include lack of knowledge, tolerance, and the potential for misuse (31).Misuse could 
be using opioids inappropriately to produce pleasure or avoid reality, using opioids in ways 
other than prescribed or accessing opioids without professional guidance.  Addiction to 
opioids can occur when a person experiences an uncontrollable impulse to use these drugs 
even when faced with negative consequences (32, 33). The Diagnostic and Statistical 
Manual of Mental Disorders (DSM-5) combines substance abuse along with addiction as a 
category of substance use disorder. The associated symptoms are categorized into four 
major levels including: impaired control, social impairment, risky use, and pharmacological 
criteria (i.e., tolerance and withdrawal) (34). In 2010, two million Americans reported 
misuse of prescription pain relievers (29). The Center for Disease Control and Prevention 
reports 46 deaths a day from overdoses of prescription and narcotic pain relievers (31). 
3.3 Non-pharmacologic treatments 
Non-pharmacologic interventions in chronic pain management include massage, avoidance 
of bedrest/staying active, cognitive behavioral therapy, physical exercise, acupuncture and 
electrical nerve stimulation. Published randomized controlled trials provide good evidence 
for the effectiveness of cognitive behavioral therapy for chronic pain in adults. Cognitive-
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behavioral treatments produced significantly improvements for the domains of pain 
experience, cognitive coping, and reduced behavioral expression of pain (35). Exercise is a 
common treatment for patients with chronic pain. Moderate to high intensity aerobic 
exercise can reduce pain while improving body function and overall health (36). Educational 
programs for patients are also considered as a therapeutic intervention which improves 
patients’ pain score (37). When education combines with exercise it synergistically 
improves self-efﬁcacy, physical function and general well-being (38, 39). Massage therapy 
and acupuncture have been used to reduce pain, but studies are few in number and evidence 
of their efficacy is not conclusive (38, 40-42). Electrical stimulation therapy had inconsistent 
evidence for efficacy in chronic pain, however a meta-analysis indicates that electrical nerve 
stimulation is an effective treatment modality for chronic musculoskeletal pain(43, 44). 
Although non-pharmacologic treatments have substantial benefits on patient outcomes, 
modalities such as behavioral therapy, electrical nerve stimulation are expensive (45). 
4. Optimizing medication-related needs in patients with chronic pain 
Optimal management of chronic pain requires understanding of pain pathophysiology by 
health care providers (46). Factors that should be considered in the optimal management of 
chronic pain are pain pathophysiology, type of pain, medical and medication history, cost-
effectiveness and evidence of efficacy, and adverse effects of treatment (27, 47). For 
instance, in selecting from pharmacological options in neuropathic pain, NSAIDs have the 
lowest efficacy in alleviating pain (15), while TCAs and anticonvulsants such as pregabalin 
and gabapentin are recommended as first line therapies (17). In treating trigeminal neuralgia, 
carbamazepine is considered a first line choice while baclofen, oxcarbazepine, and 
lamotrigine are considered alternative treatment options (47). Moreover, patients with 
similar pain conditions may have variable response to the medications within the same class 
(48). 
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Chronic pain is frequently associated with several comorbidities such as depression, anxiety, 
and sleep disorders (49). Chronic pain sufferers, especially the elderly, may have concurrent 
diseases such as diabetes mellitus and cardiovascular diseases that also require medicinal 
management. Treatment of multiple health conditions necessitates the use of complex drug 
regimens that increase the risk of drug interactions and side effects. These diverse needs in 
patients with chronic pain require collaboration amongst health care professionals. 
Pharmacists, as medication experts, can help patients with individualizing therapy based on 
their conditions and specific needs. 
5. Community pharmacy services 
The profession of pharmacy has significantly developed over the past decades. Historically, 
pharmacists have been responsible for dispensing physicians’ orders to the patients (50). 
The historical role of pharmacist as compounding and dispensing medications has evolved 
to include more patient oriented care. As drug therapy, has become the cornerstone of 
modern healthcare, management of increasingly complex drug therapies is important for 
patient safety. Rapid developments in medical and pharmaceutical sciences have led to 
increases in drug therapy that give rise to complex drug interactions and safety issues. A 
collaborative relationship between pharmacists and physicians is required due to their close 
relationship with patient health (50, 51). As described by Schellens et al. (52) ‘‘In view of 
its increasing complexity, rational and tailored drug therapy cannot be implemented in its 
full width when the discipline is applied only by physicians.’’ 
Pharmacists have a unique position within the healthcare system. They can offer a wide 
range of services to the patients including consultation, patient education, and therapeutic 
monitoring and management (53, 54). Pharmacists are currently trying to develop a more 
patient-oriented professional role for themselves. Pharmacists must be able to interact 
effectively with patients to be able to offer better pharmaceutical care (55). Although 
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dispensing the right drug for the right patient in the right dose is considered as the primary 
responsibility of pharmacists, it no longer defines the professional role of pharmacists (55). 
Pharmacists have a positive impact on patient outcomes in diverse conditions including 
hypertension, hyperlipidemia, diabetes intensive care, etc. (56-59). It is estimated that 
ambulatory pharmaceutical care services can reduce negative therapeutic outcomes by 53% 
to 63%  by reducing the drug-related morbidity, mortality and improving the patient 
adherence to medications (60, 61). 
Many patients may not appreciate the value of this expanded role of pharmacists. Increasing 
patient awareness about pharmaceutical care services will increase the patient demand for 
those services, establishing the role of pharmacists as healthcare providers. Patients who are 
educated about pharmaceutical care services are willing to receive these services and willing 
to pay for these services (62, 63). 
6. Role of community pharmacists in treatment of chronic pain 
Pharmacists are highly accessible health care providers located in a large number of 
convenient locales that can give timely advice and consultation without an appointment 
(64). Patients commonly request advice from pharmacists about their pain (65) and access 
over the counter (OTC) pain medications through pharmacies. Pharmacists, in addition to 
giving appropriate advice and information,  refer patients to physicians when necessary (64). 
Community-based pharmacists can assess the type and severity of pain, refer patients to 
other health care providers, monitor treatment (both safety and effectiveness), and guide 
medication adjustments to improve the treatment of chronic pain (65). Two types of pain 
scale instruments are usually being used to assess pain; uni-dimensional and multi-
dimensional. Uni-dimensional pain scales such as Numeric Rating Scale (NRS) or Visual 
Analog Scale (VRS) assess only pain from 0 to 10, with 0 being no pain at all and 10 being 
the worst pain imaginable (66). Multi-dimensional pain scale instruments such as McGill 
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Pain Questionnaire (MPQ) or Brief Pain Inventory (BPI) allows patients to deliver a more 
detailed description of their pain including intensity, location, quality, pattern, and 
behavioral dimensions (67-69). There are also other instruments that assess psychological 
co-morbidities such as anxiety and depression and general quality of life. Time needed to 
assess pain through unidimensional instruments can be as short as only a few minutes while 
assessment by multi- dimensional or quality of life and pain co-morbidity instruments need 
more time. Pharmacists can also educate patients on the use of their medications and 
promote adherence (65).  
In a three month interventional study, Gammaitoni et al. (70) assessed the effects of a 
telephone-based pharmaceutical care program compared to routine pharmaceutical 
programs for patients suffering chronic pain. The control group continued to receive regular 
pharmacy services (as prior to the study), while the intervention group received two 
components; specialized pain medicine prescription services and telephone monitoring of 
patient pharmacotherapy for potential drug related issues. When surveyed, the patients in 
the medication counselling group recognized the benefits of the offered services, endorsed 
the pharmacists’ behaviors associated with the enhanced pharmaceutical service, and 
reported a significantly higher level of satisfaction. This study indicates that pharmacists 
can play an important role in chronic pain management, which can lead to a better patient 
attitude toward pharmaceutical care services. 
Several other studies have investigated the impact of pharmacist consultation and 
intervention on patient health, and pain management (71-76). Pharmacists were able to 
reduce pain scores (72-75) and misuse of pain medications, particularly in the case of 
opioids in patients with chronic pain (71, 76). Pharmacists collaboration with physicians in 
chronic pain management can also lead to pain relief and improved quality of life. In a study 
of multi-disciplinary management of chronic pain (77), collaboration of clinicians including 
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internists, psychiatrists and pharmacists, along with alleviating patients’ pain, led to 
improved patients’ quality of life. Improvements in quality of life mostly attributed to 
reduced disability, comorbid disorders and decrease in incidence of medication misuse.  
The cost effectiveness of pharmacists’ services in pain management also has been 
demonstrated. In a study of managed approach to opioid therapy in collaboration with 
pharmacists,  significant cost savings through monitoring opioids treatments, reduced 
misuse  and referring the addiction patients is demonstrated (76).  
7. Knowledge barrier for pharmaceutical pain management services 
Pain is considered a public health problem in that its management encounters a series of 
deficiencies. Although pharmacists are expanding their professional skill to offer more 
patient oriented care including chronic pain management, they may not be sufficiently 
trained to offer this service. In a study of the knowledge and attitudes of healthcare 
professionals including pharmacists regarding pain issues such as addiction, the assessment 
of pain, scheduling and use of analgesics, investigators concluded that although the 
healthcare professionals were familiar with some aspects of pain management, gaps in 
knowledge existed (78).  
In a study of pharmacists’ attitudes and knowledge concerning back pain, Silcock et al. (64) 
sought to understand the nature and variety of advice that patients with back pain were likely 
to receive in the community pharmacy setting. About one third of pharmacists wrongly 
advocated rest and limiting normal activity. Notably, 93% of participating pharmacists 
agreed that they would benefit from education about chronic back pain. Approximately 20% 
of pharmacists did not feel confident to provide the best advice to patients and had negative 
feelings about advising patients with back pain. This study showed that pharmacists were 
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willing and available, yet inadequately educated and not confident to provide evidence 
based advice to people with low back pain. 
8. Satisfaction with pain management 
8.1 Satisfaction and Quality in Healthcare 
Patient satisfaction with treatment has been defined as the extent to which treatment gratifies 
the wants, wishes, and desires of clients for service (79). Weaver (80) defines treatment 
satisfaction as the individual’s rating of important attributes of the process and outcomes of 
his/her treatment experience. 
The relationship between healthcare quality and patient satisfaction has been a source of 
debate (81). On the grounds that service quality was wrongly interpreted as patient 
satisfaction, satisfaction has been investigated and measured widely as the sole parameter 
of quality of care assessment studies (82). However, there is little work in investigating 
patient perceptions of general health service quality (83, 84). Gonzalez et al. (85) states that 
satisfaction questionnaires have been used as the most common method to survey patient 
perceptions of health care for many years without being well validated. A review of 
literature in patient satisfaction points out that none of the measurement methods could be 
considered satisfactory and numerous satisfaction studies have been conducted without 
considering sufficient psychometric evidence (86). To date, no agreement on the definition 
and conceptualization of satisfaction with healthcare has been developed (84, 86, 87). 
According to Crow et al. (87), satisfaction is a relative concept that only can signify 
adequate service that could be affected by emotion (84, 87), They considered core 
determinants of satisfaction as the basis of interpersonal relationships (87). Moreover, 
several aspects of satisfaction with healthcare provider services should be differentiated 
(80). For example, in a study of patient satisfaction with treatment for chronic pain (88), 
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authors emphasized distinguishing between satisfaction with care and satisfaction with 
improvement. Finally, in pain management, patient satisfaction with treatment may not be 
inferred as pain relief (88). 
8.2 Inadequate Pain Management as Patient Dissatisfaction with Pain Control 
Patient satisfaction with treatment has been investigated extensively in variety of medical 
illnesses (88). Several studies showed that inadequate pain control can be implied as patient 
dissatisfaction with pain control. A four year follow up study in patients with chronic pain 
in the UK reported that two thirds of chronic pain sufferers were not satisfied with their 
treatment (89). Furthermore, only 21.5% of the patients were pain-free at the 4-year follow-
up, resulting in an annual improvement rate of 5.4%. In another follow up study on patients 
with chronic musculoskeletal pain in the US (90), 34.6% of the study population were pain-
free after 8 years. In a Norwegian study (91), 14.3% patients were pain-free at the 5.5 year 
follow up, showing low recovery rates in chronic pain. 
Despite its high prevalence, chronic pain remains misunderstood and poorly managed (92). 
As Zuccaro (93) noted, “Chronic pain is inadequately treated because of a combination of 
health care providers knowledge and attitudes toward pain treatment along with cultural, 
societal, educational, political and religious constraints.” For instance, in some cultures 
acceptance of pain is normal and attitudes toward pain is summed up to bear the pain. As 
illustrated in observational studies, in some cultures, despite high prevalence, pain is not 
perceived as a medical problem and sufferers do not seek medical treatment (94). 
Low recovery rates cannot be interpreted as low satisfaction rates since there is a difference 
between satisfactions with care and satisfaction with improvement. In other words, 
satisfaction may not be directly correlated with low pain levels. Other factors such as 
patient-provider relationships can also affect patient satisfaction  (88). 
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9. Investigating Pharmacists and Patients Interactions/Relationship 
9.1 Significance of pharmacists and patient attitudes toward pain management 
Practitioner beliefs and attitudes can influence treatment decisions in chronic pain(95). 
Beliefs about to the extent to which pain can be controlled is one of the most potent 
determinants of adjustment to pain (96, 97). According to Main et al. (97), patients’ 
attitudes, perceptions, and expectations about pain and the usefulness of offered treatments 
may influence a patients’ decision to pursue complete treatment (88), as well as affect the 
patients’ engagement and adherence to treatment. In a study of chronic pain patients’ 
experience of acupuncture (96), patient’s experiences of early treatment sessions influenced 
their expectations and treatment outcomes. Positive attitudes toward treatment led to 2 to 5 
fold greater likelihood of improvement (96) and these patients experienced better outcomes 
(64). 
 Researchers emphasized the necessity of qualitative research for the development of tools 
to measure patient expectations and attitudes. 
Moreover, perceived quality of service is associated with a significant reduction in total cost 
of service results due to the elimination of wasted effort, repetition, and misuse of skilled 
employees. In controlled studies of diabetes, asthma, hypertension, and rheumatoid arthritis, 
increases in service quality resulted in improved outcomes (98). 
9.2 Pharmacists’ attitudes 
Several studies have investigated pharmacists’ attitudes toward the pharmaceutical services 
they offer. In one of the earliest surveys on pharmacists’ perception of their consumer 
demands in 1983 (99), researchers realized that pharmacists perceived little demand for 
pharmacy services and they usually underestimated demands for these services. A recent 
systematic review of pharmacists and costumer views (100) shows that the perception of 
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little demand by patients still existed among pharmacists worldwide. Pharmacists’ 
perception of consumer demand is as important as actual consumer demand in providing 
pharmacy services. A survey of 708 pharmacists regarding their perceptions of patients’ 
need for counselling (101), showed that patient motivation was ranked as the highest 
determinant of the amount and type of counseling, followed by type of medication, patient 
abilities, and time available for counselling. 
9.3 Patients’ attitudes 
Patients have their own perception of the pharmaceutical services they receive. Several 
studies have evaluated patient satisfaction with pharmaceutical services in patients with 
asthma, hyperlipidemia, hypertension, and heart failure (102-104), but the major 
determinant of patient satisfaction was not the value of the pharmaceutical care provided by 
the pharmacist (105). While most of those studies showed a high rate of satisfaction 
signifying that pharmacists are highly respected professionals (87), these studies did not 
measure all influences of patient perception of pharmaceutical care. For example, increased 
contact and personal attention from the pharmacists and health care providers affect 
patients’ perception (106, 107). These outcomes to some extent confirms the results of the 
previous similar study (101) that showed patients who received longer consultations were 
more likely to report higher satisfaction scores. 
According to Raid et al. (108)  “reports of satisfaction with care do not necessarily mean 
that the pharmacists are providing a high quality level of pharmaceutical care. They also 
may mean pharmacists deliver prescriptions in a fast, courteous manner and have good 
interpersonal relationships with their patients, even though the patient is getting little in the 
way of education and monitoring”. Customers can classify the same pharmacist differently 
on the grounds that patients use their own interpersonal meta cognitions and stereotypes to 
interpret a pharmaceutical service. This highlights the importance of an in-depth evaluation 
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of patients’ judgment and perception of the value of the services. In a study of perception 
of asthmatic patients and their satisfaction of their pharmacists, investigators tried to 
understand the relationship between patient satisfaction and the level of pharmaceutical care 
service and patient perception of the personal attention paid to them by the pharmacist and 
pharmacists’ ability to help their asthma related problems through a survey on 250 adult 
patients with asthma (108). Results of this study showed that although patient satisfaction 
was associated with the level of pharmaceutical care and pharmacists’ capability to help 
their problems, personal attention to the patient by pharmacist had the most influential effect 
on patient satisfaction. Authors conclude that patients mostly judged their social interaction 
with pharmacists rather than the quality of the care they receive.  
10. Significance of studying patient-pharmacist perception of pain control management 
Patients commonly request advice from pharmacists about chronic pain. Practitioner beliefs 
and attitudes can influence treatment decisions and patient perception of disease. Perceived 
quality of care can improve adherence, continuity of care and health outcomes  (109-111). 
Pharmacists’ self-perception of their professional role can influence  changes toward more 
patient-centered care (112). They have the potential to take on an enhanced role for a variety 
of conditions including chronic pain. However, in a study of pharmacists’ perception on 
their professional role (113), only 29% of pharmacists perceived their role as patient 
centered while 45% of pharmacists perceived their role as product focused, and 26% had an 
ambiguous perception of their professional role. Lack of time, training compensation, and 
support from other health care professionals have been reported as common barriers to 
patient-centered services (113-115). 
The investigation of pharmacist and patient attitudes on chronic pain management can 
address knowledge and skill gaps in pharmacists’ profession and potentially translate into 
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positive health outcomes for patients. Moreover, better understanding of pharmacist’s 
experience and perception of the value of pharmacy services can influence their practice 
and help pharmacists plan patient-centered services. 
The aim of this study is to investigate aspects such as feelings and experiences of 
pharmacists providing care to patients with chronic pain in the community setting. In 
medical sociology, qualitative methodologies are accepted and recommended as significant 
tools to analyze subjective attributes of health services (116, 117). Through the descriptive 
and interpretive nature of qualitative methods a true and profound understanding of 
pharmacists’ perception of providing care to patients with chronic pain can be investigated. 
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Objectives                                                                                                                              
To explore community-based pharmacists' perceptions and experiences of providing care 
to patients with chronic pain including: 
- Pharmacist’s role in providing care to patients with chronic pain 
- Pharmacist perceptions of patients with chronic pain. 
- Pharmacist concerns and barriers for providing care to patients with chronic pain 
- Pharmacists’ communication with physicians / prescribers in providing care to patients 
with chronic pain  
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Methodology 
1. Qualitative studies 
Qualitative research, which focuses on the social world rather than the natural world (118), 
is designed to understand and interpret social interactions rather than testing hypotheses and 
evaluating cause and effect as occurs in quantitative research. Variables in qualitative 
research are not specific as they are in quantitative research. Types of data in qualitative 
studies are words and objects rather than numbers (119). Denzin (120) describes qualitative 
research as “the word science”. It relies heavily on words and stories that people tell the 
researchers (121). It is a kind of social inquiry that looks at how individuals understand and 
explain their experiences and the world in which they live (122). As a consequence, the 
results of qualitative studies are less generalizable in comparison to those of quantitative 
studies whose findings have the potential be applied to other populations (123). 
The rationale for conducting qualitative research includes (118, 121, 124): 
- When the researcher has no knowledge about the phenomenon under investigation. 
- When there is a need to understand the context of research participants’ life. 
- When it is necessary to “hear people’s voices”. Some details can only be obtained 
by talking with people directly to hear their stories and experiences. Qualitative 
research enables researchers to listen to actual voices. 
- When there is a need to develop theories that can explain the complexity of an 
individual or a population’s problem. 
- To understand complex issues that need to be explored, especially when describing 
phenomena from the participants’ point of view is required. 
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- When causal explanations from qualitative research need to be elaborated, especially 
when researchers are not able to explain numerical findings logically. 
Characteristics of qualitative research described by Liamputtong (118) are listed below: 
- It takes place in natural procedures of human life. 
- It focuses on context. 
- It is fundamentally interpretive; the centerpiece of qualitative study rotates around 
meanings and interpretation of participants. 
- It is mostly emergent rather than strictly predetermined. 
Several methods in qualitative research are available including ethnography, narrative 
studies and grounded theory. Each designed for investigating a specific research questions, 
but all share a similar goal: to understand a particular phenomenon from the perspective of 
people experiencing it (125). 
2. Popular approaches in qualitative studies 
2.1 Narrative inquiries  
Narrative inquiries is the most appropriate method when the researcher is interested in 
personal experiences of people, consisting of the collection and development of stories 
(126). According to Duque (127), core elements of narrative study are attention to sequences 
of action, choice of language, narrative style, and varying degrees of analytic interest in 
audience/reader response that can be used to compare and contrast narrative methods with 
other methods of qualitative studies. 
2.2 Ethnography 
 In ethnography, the researcher’s goal is to understand how a culture works. Lutz (128) 
points out: “ethnography centers on the participant observation of a society or culture 
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through a complete cycle of events that regularly occur as that society interacts with its 
environment.” In ethnography the ethnographer’s goal is to study a society, to be able to 
describe the meaning, organizations, values, attitudes, and interpretations of a culture (129). 
In other words ethnography helps researchers to understand people’s behaviors from their 
own cultural perspectives (130). 
2.3 Qualitative case study 
 Qualitative case study research is a qualitative approach in which the investigator explores 
a bounded system (a case) or multiple bounded systems (cases). This approach facilitates 
exploring a phenomenon within its context using a variety of data sources. Data collection 
is detailed and in-depth through multiple sources of information (e.g., observations, 
interviews, audiovisual material, documents and reports) (131). 
In a case study, the researcher reports a case description and case-based themes. For 
example, several programs (a multi-site study) or a single program (a within-site study) may 
be selected for study. Case study is a valuable for studying health science research to 
develop theory, evaluate programs, and develop interventions. 
Qualitative case studies are categorized according to the size of the bounded case; one 
individual, several individuals, a group, an entire program, or an activity. Creswell (132) 
says “A case study is a good approach when the inquirer has clearly identifiable cases with 
boundaries and seeks to provide an in-depth understanding of the cases or a comparison of 
several cases.” 
Creswell(131) defines three types of case study: 
- Single instrumental case study: In this method, the researcher focuses on an issue and 
tries to illustrate this issue by selecting one bounded case. 
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- Collective (multiple) case study: The issue or concern is one but the researcher uses 
multiple case studies to illustrate several perspectives of the issue. For example, studying 
several programs at multiple sites or several programs on a single site. 
- Intrinsic case study: The focus is on the case itself. The case is an unusual or unique 
situation, such as evaluating a program. 
2.4 Grounded theory 
 Grounded theory is a popular method in qualitative research that provides the opportunity 
to researchers to generate and construct an explanation based on what researchers have 
learned from a number of participants (118) and a theory will be generated from the data. 
Aldiabat (130) defines the aim of grounded theory as “to generate theory that describes basic 
psychosocial phenomena and to understand how human beings use social interaction to 
define their reality.” To generate a theory that defines a phenomenon, researcher should 
recruit a substantial number of participants to reach data saturation. This necessitates 
spending substantial amount of time and budget. To overcome these limitations and making 
grounded theory more practical, a modified grounded theory has been developed. 
2.4.1. Modified Grounded Theory Approach (M-GTA) 
 Modified Grounded Theory enhances the practical applicability of grounded theory by 
adding some modifications, adopting theoretical and content properties of the grounded 
theory (133). In comparison with Grounded theory, in M-GTA, fewer number of 
participants are required and data are analyzed according to an analytic theme raised based 
on analytic target’s viewpoint which is decided on the basis of the research question chosen. 
This means that in analysis of data, the researcher focuses mostly on the research question 
and related themes. The data are not broken down into fragments for coding in this method, 
thus it is possible to find the context meaning at the root of raw data. Since analytic theme 
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and target are decided on the basis of the research question, a clear research question is of 
great importance in M-GTA analysis (133). 
To understand perception and experience of pharmacists providing care to patients with 
chronic pain, which can be applied to address gaps and deficiencies in providing care to 
patients, our research team decided to use a Modified Grounded Theory Approach. Because 
Modified Grounded Theory investigates the actualities in the real world and analyses the 
data with no preconceived ideas or hypothesis (134) when we need to explain how people 
experience a phenomenon (providing care), by using Modified Grounded Theory, 
researchers will be able to raise a high quality theory that explain such a phenomenon. It 
allows researchers to develop theoretical frameworks that explain research findings (118). 
3. Setting and Participants 
The setting for this study was the province of Ontario.  
4. Procedures 
4.1 Recruitment 
The research question of this study was “What is the experience and perception of 
pharmacists concerning providing care to patients with chronic pain management?” 
Ontario-licensed pharmacists who were actively practicing in a community pharmacy or a 
family health team settings were recruited to address the question under study. Participants 
were recruited by means of a recruitment poster and invitation letter embedded emails 
(Appendix 4). The posters and invitation letters included a brief background on the research 
topic and study purpose and listed all conditions, expectations, and a summary of interview 
questions from pharmacist volunteers (i.e. what will be asked from study participants in 
terms of interview and methods of data collection employed). Contact information; 
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telephone number, and e-mail address were included on the poster to volunteer for the study 
and/or for further inquiry. 
The list of email address of licensed pharmacists who had indicated their interest and 
willingness to participate in research studies was provided by the Ontario College of 
Pharmacists (OCP). Those pharmacists who responded and indicated their willingness were 
emailed a study information letter and consent form. 
All volunteers responded by email. Screening of volunteers was carried out to ensure 
recruitment of only those who qualify for the study; namely, Ontario licensed pharmacists 
who were actively practicing in community pharmacy or family health team settings. 
Pharmacists who were not practicing in community pharmacy or family health teams (e.g. 
those who were working in hospitals, nursing homes or pharmaceutical companies) were 
excluded from the study. This type of recruiting is known as Purposive Sampling or 
Purposeful Sampling. This method of sampling, which is frequently used in qualitative 
studies, is a non-probability method that involves the selection of certain individuals whom 
the researcher hopes to include in the study based on the study objectives (135). In this 
method of sampling, the researchers researcher targets are individuals who are wealthy with 
information required to fulfil the project’s purpose of study (136). 
4.2 Data collection 
Data collection took place from July 2016 to August 2016. As expected with Modified 
Grounded Theory, data collection overlapped with data analysis and was carried out 
simultaneously. Participants were invited for one-on-one semi-structured interviews at their 
choice of the interview setting; at the pharmacy, at home, or a mutually agreed upon public 
site such as a room within a community library. For participants who could not travel, 
interviews over telephone would be held. Interviews were recorded on a digital voice 
23 
 
recorder while I tried to take notes of important parts of interview that later can be used as 
a guide for coding the data. 
Participants’ demographic data including age, sex, and pharmacist practice data including 
age, gender, level of education, practice years, working setup and geographical location, 
also were collected for further analysis (Appendix 1). 
5. Interviews 
Individual face-to-face, semi-structured interviews were chosen as the method of obtaining 
information from participants. This type of interview provides the interviewer with 
sufficient flexibility without allowing the respondent to lead the interview and deflect to 
irrelevant subjects. The major benefits of this type of interview include the ability to develop 
rapport and gain participants’ trust as well as an in-depth understanding of the responses 
(135). In semi-structured interviews participants have the opportunity to express their 
opinion in their own words while the interviewer can maintain focus. This allows the 
researcher to co-facilitate data creation without getting off topic. 
Prior to the interviews, interview questions were developed by our research team. Questions 
were developed to outline participants’ experience in pain management. The interview guide 
covered six main topics for discussion; the introduction (demographic data gathering), 
feelings and concerns about patients with chronic pain, opioids, communication with health 
care providers, and training. On the grounds that interviews are semi structured, some 
questions might be different depending on the participants’ response (Appendix 2). The 
majority of interviews were approximately 50-60 minutes in length.  
Before the interviews, through an e-mail, the participants were provided with an 
information-consent letter of the study that outlined the purpose and objectives of the study, 
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the participants’ ability to withdraw from the study at any time and affirmed clearance from 
the Office of Research Ethics at the University of Waterloo. 
The consent form indicated consent for interview, audio-recording of interviews, and use of 
anonymous quotations in future research and/or publications. All participants agreed to 
these conditions and signed the associated documents. 
At the beginning of the interview I would remind patients about the audio recording the 
interview and their ability to quit the study during and after the interview. Interview 
questions were answered based on each pharmacists’ perception of their role and experience 
of patients with chronic pain. 
Sometimes, during my interviews with pharmacists, some participants diverted to a topic 
that was not listed in my interview guide, but led to derivation of some valuable information 
for the study. At the end of interviews participants were asked to share any point of view 
about chronic pain that they think it is important, but were not covered in our interview 
guide. 
Post-interview, audio recordings were labeled using codes (for participants) and transcribed 
by a member of the research group. Audio recordings and transcriptions were securely 
stored in an encrypted folder in a computer in my office cabinet. Labels facilitated handling 
the collected data while maintaining participants’ anonymity. 
In qualitative research, the point of saturation plays an important role in choosing a suitable 
number of participants. The sample size in qualitative studies is decided based on thematic 
or theoretic saturation. Data saturation is the point at which no new data or themes are 
emerging from the data. Guest and colleagues (137) found that basic elements for meta 
themes can be present as early as six interviews. Morse et al. (138) reported that 8–12 
25 
 
participants can be an acceptable sample size for detailed description of participants’ 
experience. 
I initially targeted a sample size of 8–12 pharmacist participants while acknowledging that 
this number was subject to change based on the theoretical saturation of categories.  
6. Data analysis in qualitative study 
6.1 Constant comparative method 
The constant comparative method is an ongoing procedure that compares newly collected 
data with previous data. This method of analysis is mainly used in grounded theory and case 
study approaches. 
The basic concept of qualitative analysis is to read the textual database (usually transcribed 
from audio recordings) and documents, discover data variables that are called categories 
and meaningful units of participants' experience, to detect their relationships. The ability to 
distinguish variables and data is called "theoretical sensitivity" (129). In the other word, 
theoretical sensitivity is a conceptual term which means the ability to give meaning to data 
by understanding and separating the pertinent from that which is not (139). 
After transcribing the recorded interviews, data should be analyzed before proceeding for 
further interviews. This can help to orient subsequent interviews as data collection and 
analysis are interrelated processes. According to Corbin and Strauss (130), "in grounded 
theory, data analysis start as soon as the first bit of data is collected." Thus, the analysis 
from the start of the study directs the next interview and observations. In order to not miss 
anything that may be important, the researchers must analyze the first bits of data for cues 
and all supposedly relevant points should be considered in next interviews. Data analysis in 
current study started after first two interviews. The analysis procedure is described below. 
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6.1.1 Transcribing 
In transcribing interviews, all interviews are transcribed verbatim from audio records. All 
transcripts will be double checked for accuracy. Then, transcripts are imported to qualitative 
analyzing software for further analysis. 
6.1.2 Coding 
Bailey (140) defines coding as “process of organizing a large amount of data into smaller 
segments that, when needed, can be retrieved easily”. Coding is the core analytic process of 
qualitative research that is done by the researcher. As interviews progress, the expanding 
codes will be shared among research team members and the codes will be discussed for 
categorizations. Labels will be compared to each other and then categorized. This 
categorization of data allows the generation of a tentative conceptual framework. Each 
category will be titled by examining common palpable themes and concepts. Several 
tentative categories will be classified to a core category (141), determined by examining 
different categories. This list of codes is used to orient further interviews. The process of 
coding in grounded theory consists of open coding, axial coding and selective coding. 
6.1.3 Open coding 
Initial coding is known as open coding. Data are broken down by the researcher to find 
insights reflected in the data. Corbin (142) says “In open coding, events, actions, and 
interactions are grouped together for similarities and differences. They are also given 
conceptual labels. In this way, conceptually similar events/actions/interactions are grouped 
together to form categories and sub categories.” Using constant comparison in open coding 
enables investigators to break through subjectivity and bias (142). 
In open coding, transcribes are read line by line to understand overall context, notes are 
taken and coding schemes developed by identifying the data that is relevant to the study 
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purpose and research question, that can be called “Units of meaning” of participants’ 
experiences in the data by searching for answers to questions such as “What is this about? 
What is being referenced here?” Analysis process in open coding rotates around identifying, 
naming, listing, categorizing, and describing the phenomena found in the textual data. A 
part of the analytic process is to determine the more general categories for primary 
categories and listings. For example, for labels such as hospitals, friendship, and social loss, 
we can use institutions, social relations, and social outcomes (142). 
6.1.4 Axial coding 
Axial coding is also known as focused coding and seeks to identify relationships between 
open codes. The researcher tries to understand categories in relationship to other categories 
(143), and relate these codes (categories) to each other to make larger categories. The larger 
categories should be related to their subcategories and the association tested against data 
(142). 
6.1.5 Selective coding 
Selective coding is the process of choosing one category to be the main category and trying 
to relate all other categories to the selected category. Those categories that are poorly 
categorized, (few properties have been uncovered in the data or subcategory contains only 
a few explanatory concepts) and/or need to be explained more, are most likely to be 
identified in axial coding (142). The core category should portray the cardinal phenomenon 
of the study. If findings of the study are to be summarized in a few sentences, what would 
the researcher say? What does all action/interactions rotate around (142)? 
6.2 Content analysis 
This method helps to understand the data of the study. It mainly consists of coding according 
to the unit of analysis (what to analyze and to what detail) and checking the reliability of 
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coding and categorizations. After coding, data can be analyzed using frequency counts, 
category ranking, multivariate analysis of variance and multiple regression methods (135). 
6.3 Memo-writing to capture reflections on the collected data 
Memos are a type of document that provide the researchers with the ability to record the 
ideas, insights, interpretations or growing understanding of the material of the project. 
Memos are considered as mini-analyses about what the researcher is thinking or learning 
within the analyses process. Memos are short documents that researchers write to 
themselves as they proceed through the analysis of a body of data. Writing analytic memos 
is a critical phase of qualitative analysis. It provides the basis of analyses that will end up 
carrying the final report. Qualitative researchers usually write memos both during 
(interviews) and after (reading the data and data coding) data collection. Memos should 
reflect concepts and patterns that are emerging in data and what is or is not evident in data. 
Memo writing allows researchers to compare and contrast connections within and between 
datasets (144). Charmaz (145) remarks “Memo-writing forces you to stop other activities; 
engage a category, let your mind rove freely in, around, and from the category; and write 
whatever comes to you.” They can be a summary of core findings and comments on specific 
parts of the data while the researcher faces within the analysis process. Moreover, it can 
provide a medium for thinking about any additional data that would be helpful to collect in 
order to complete the analysis. To keep track of hypotheses and categories that have been 
elaborated during the analysis procedure, researchers must use memos. It should begin from 
the first coding session and continue through to the end of the study. Data from this process 
can be used for subsequent analysis. Figure-1 illustrates a schematic process of data analysis 
of a transcribed text from reference (139). 
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7. Software 
Numerous software packages are available for analyzing qualitative studies that help 
researchers to manage, organize, and shape unstructured data. Qualitative research software 
do not do the thinking for the researcher, but give researchers more time for data analysis 
of their materials by building research tools that facilitate sorting and categorizing 
information. Software helps by taking notes in the field, editing, coding, memo-writing, 
storage, finding sequence locations and frequencies, and building theory (146). 
 For data analysis of our study we used NVivo® (QSR international, version 11, 2016), 
which has features and tools to facilitate organizing data for coding and memo-writing. It 
also facilitates theory building from the data. 
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Figure 1- Data analysis process in grounded theory 
Open 
Coding 
Memo Writing 
Writing notes to oneself during the interviews and data analysis, regarding the coding and 
what the researcher understand based on the data. For example, for the above text a 
memo could be: Patients think that arthritis pain is quite consistent 
The recorded interviews are transcribed verbatim. 
“Pain relief is a major problem when you have arthritis. Sometimes, the pain is worse than 
other times, but when it gets really bad, whew! It hurts so bad, you don't want to get out 
of bed. You don't feel like doing anything. Any relief you get from drugs that you take is only 
temporary or partial.” (Transcribed text fragment sample is taken from reference 145) 
 
 
Themes and Theory will be developed based on analysis of other parts of the data and 
comparing them 
Coding 
Axial 
Coding 
One thing that is discussed here is PAIN. Participant’s view has some 
properties such as Intensity, Pain relief, Duration, and Effectiveness. 
From the text, it is obvious that the topic of interest is Pain persistence in 
arthritis patients. However, by considering other fragments of the text 
researcher can elaborate other axial codes. 
Selective 
Coding 
Selective coding is the process of choosing one category to be the core 
category. Here impact of pain in arthritis patients’ life can be considered 
as the Core category 
Transcribing 
Development 
of Themes and 
Theories 
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Findings  
This chapter focuses on the themes that emerged from participants’ interviews that reinforce 
the experience and perception of pharmacists about chronic pain management. In the 
following section, the results will be discussed thematically with common experiences 
gathered into clusters.  
Twelve pharmacists volunteered to participate in the study. Two of these were excluded 
because of their setting of practice (hospital rather than community pharmacy or family 
health team), and one opted to quit the study before the interview time due to a death in the 
family. Two interviews were carried out face-to-face in a private interview room or in the 
pharmacist’s workplace. The remaining interviews were one-on-one telephone interviews. 
Telephone calls were made from a private interview room at the School of Pharmacy.  Data 
saturation occurred by 7th interview. Two additional interviews were conducted which did 
not identify additional themes. 
Demographics information 
A purposive sample of nine pharmacists working in Ontario participated in this study. Of 
the participants, three were male and six were female. The majority were older than 40 years 
old, mean age 46. A community pharmacy was the primary place of practice of five 
pharmacists, two pharmacists were from family health teams and one pharmacist was 
working in both community and family health team settings. Two pharmacists had residency 
training, one had a Pharm.D. degree and one had a Ph.D. with an academic background. The 
remaining five pharmacists had a B.Sc. in pharmacy. Except for two pharmacists, all 
pharmacists were practicing in urban communities. Regarding the practicing experience, the 
mean years of experience was 19 years, ranging from 2 to 40 years. Excluding one young 
pharmacist who had 2 years practicing experience as a community pharmacist, all had at 
32 
 
least 10 years of experience. The average time spent de dealing with patients with chronic 
pain by pharmacist participants is 30%. 
 
Table 1- Demographic characteristics of participant pharmacists 
 
Gender 
 
Age 
Range 
(Years) 
 
Degree 
 
Practice 
setting 
 
Chain vs 
Independent 
Population 
of the 
practicing 
Town/city  
 
Years 
of 
Practice  
Percentage 
of time 
dealing with 
pain 
 
F 
 
40-49 
BSc(Pharm) 
+ 
Residency 
Family 
Health Team 
 
NA 
 
150,000 
 
22 
 
20% 
F 40-49 BSc(Pharm) Community Independent 150,000 15 15% 
 
M 
 
40-49 
BSc(Pharm) 
+  
Ph.D. 
 
Community 
 
Chain 
 
210,000 
 
25 
 
25%-33% 
M 20-29 Pharm. D Community Independent 360,000 2 50% 
F >60 BSc(Pharm) Community Independent 1,000,000 40 30% 
F 50-59 BSc(Pharm) Community Independent 2,000 18 40% 
 
F 
 
40-49 
 
BSc(Pharm) 
Community 
and 
Family 
Health Team 
 
Independent 
 
50,000 
 
10 
(21)** 
 
       15% 
 
M 
 
50-59 
 
BSc(Pharm) 
   
Community 
 
Chain 
 
5,000 
 
20 
 
50% 
 
F 
 
40-49 
BSc(Pharm) 
+ 
Residency 
Family 
Health Team 
 
NA 
 
1,000,000 
 
22 
 
20% 
* Ph.D. in Medicinal Chemistry. 
** 10 and 21 years practice in community and industry respectively. 
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Table 2-  Comparison of study pharmacists to population of practicing pharmacists in 
Ontario* 
Characteristics No of participant pharmacists n=9 
(percentage of population) 
No of Ontario pharmacists in 2014, 
n=13207 
(percentage of population) 
Sex 
Male 
Female 
 
3 (33%) 
6 (67%) 
 
5591 (42.3%) 
7616 (58%) 
Age 
<30 
30-39 
40-49 
50-59 
≥60 
 
1 (11%) 
0 (0%) 
5 (56%) 
2 (22%) 
1 (11%) 
 
1569 (12%) 
3455 (26%) 
3576 (27%) 
2811 (21%) 
1796 (14%) 
Education 
BSC in Pharmacy 
Entry level Pharm.D 
Pharm.D 
MSc. Pharm 
Residency trained 
 
 
8 (89%) 
1 (11%) 
0 (0%) 
0 (0%) 
2 (22%) 
 
 
12468 (94%) 
- (-) no data 
391 (3%) 
233 (2%) 
-(-) 
 
Years of Practice 
0-10 
11-20 
>20 
 
2 (22%) 
3 (33%) 
4 (44%) 
 
3662 (28%) 
3319 (25%) 
6188 (47%) 
* Data from Canadian Institute for Health Information 
 
 
Figure 2- Geographical distribution of study participants in Ontario 
 
34 
 
Major themes and sub-themes 
This chapter presents the data gathered and analyzed and the themes that emerged from 
participants in this study that illustrates their in-depth individual experiences and the 
perceptions of participant pharmacists about chronic pain management in their daily 
practice. From the transcribed interviews, 735 significant quotations were extracted and 
categorized in 264 cluster codes. These codes were merged into five main themes. Each 
theme will be presented individually with supporting verbatim quotes from participants’ 
transcripts. 
The five major themes were: 
1) Perception of chronic pain (chronic pain management) 
2) Opioids 
3) Patients’ concerns 
4) Communication with prescribers 
5) Knowledge gaps 
These themes portray the significant experience of pharmacists about chronic pain 
management. Each overarching theme is constituted of subthemes that fall into that category 
of meaning. These subthemes are shown in Table 3. Each theme will be presented 
individually with supporting verbatim quotes from participants’ transcripts. 
 
 
 
 
35 
 
  
Table 3- Major themes and sub-themes 
Themes Sub- themes 
 
Perception of chronic pain 
Understanding of chronic pain 
Perception of patients with chronic pain 
Perceptions of pharmacists’ role 
 
Opioids 
Misuse (Addiction, Diversion) 
Inadequate monitoring 
Inappropriate use of medications and treatments 
 
Patients’ concerns  
Inadequate pain control 
Lack of support 
Addiction 
 
Communication with prescribers 
How pharmacists think about communication 
Barriers in communication with prescribers 
How to improve the communication 
 
Knowledge (education) gaps 
Knowledge about chronic pain 
Knowledge about legal issues 
Communication skills 
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Figure 3- Theoretical framework of perceptions and experiences of community pharmacists 
interacting with patients with chronic pain 
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1. Perception of chronic pain management 
As this study focuses on experience and perception of pharmacists in chronic pain 
management, I tried to provide a brief picture of pharmacists’ perception about the major 
elements in chronic pain management by pharmacists: Chronic pain, patients and their role 
as pharmacists. 
1.1 Understanding of chronic pain 
After asking participants’ age, practice setting, and other demographic information, I asked 
them questions about their understanding of chronic pain and how they define chronic pain 
based on their experience. Pharmacist participants defined chronic pain in similar 
perspectives. Almost all pharmacists addressed the core characteristics of chronic pain such 
as unknown etiology and chronicity (more than 3-6 months) of pain. Some pharmacists also 
widened their definition of chronic pain by commenting on association of disorders such as 
anxiety, depression, disability, and impaired quality of life in chronic pain. 
“For me, it’s something that just doesn’t go away, and it’s more than 3 months. It’s just 
not going away, doesn’t seem to matter what you do, you still have it. It adversely 
impacts your quality of life.” P5 
 
“Pain that lasts more than — well — more than 3 months or past the time when an acute 
injury has healed and that you would expect the pain to have resulted.” P9 
 
“We can do it from a definition if anything. It’s pain that persists beyond the healing of 
tissue and beyond that 3-6 months, and you know I see 3 months and I see 6 months. So, 
anything that’s persistent, and especially in the absence of any acute injury. And that is 
ever present, and that is impacting the level that’s effecting the quality of life in a variety 
of domains.” P1 
 
“chronic” is associated with “long-term”, so we’re dealing with pain that is due to a 
physical condition that’s lasting — again, depending on who you talk to — maybe lasting 
for a month, maybe lasting for a couple of months. We’re dealing with a full spectrum of 
symptoms from anxiety, from depression, from even organic effects on blood pressure 
and sugar control.” P3 
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1.2 Feelings about patients with chronic pain 
Some participants continued the interview by describing their perception of patients with 
chronic pain. They believed that the suffering of pain and disability are visible in patients’ 
appearance. This perception was associated with a feeling of empathy to patients with 
chronic pain. However, participants had not noticed any other significant difference in 
dealing with patients with chronic pain and other patients. 
 “Think the people with true chronic pain, to me, always look like they have a black-cloud 
over their head. They always look sad, they look depressed. They look unhappy. The 
people with true chronic pain, their quality of life, their joy in life, is not sustained.” P5 
 
“I keep in mind that this is a chronic disease, it is different from acute pain. You are 
actually dealing with physiological, organic changes in your nervous system, after months 
and months of suffering through pain.” P3 
 
These are patients who have pain and have a lot to say. These patients need help from all 
their healthcare professionals, because it can be a very debilitating and very painful 
condition to have. P2 
1.3 Perception of the pharmacists’ role 
Pharmacists in this study believed they can play an important role in chronic pain 
management. Some pharmacists were of the opinion that they are very accessible by 
patients, which accounts for the decent role of pharmacists among health care providers in 
pain management. 
“I think that we still have a pretty decent role in terms of those kinds of questions. Like 
we’re more accessible than your family doctor I would say. Like anybody can go into a 
Shopper’s.” P4 
 
“Oh, it’s huge (the role)! So, a pharmacist and a physician together make an excellent 
team. You know, in terms of — once a physical exam has been done and the imaging is 
done and you kind of know what you’re dealing with in terms of a pain problem, a 
pharmacist who is experienced, is as good as a physician’s experience in terms of 
suggesting medications, managing side effects, adjusting doses, you know, that sort of 
thing” P9 
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Pharmacists felt that they can help patients with pain when they are looking for over-the-
counter medications or when they have a prescription for pain. When asked about non-
prescription medications for pain, participant pharmacists would try to assess patients’ pain 
by asking about severity, duration, and possible etiology of pain to offer the best medication 
for their condition or referring them to a physician. When I asked interviewees about 
referring patients to other health care providers, all of them mentioned family physician as 
the sole health care provider they referred their patients. 
“First of all, I ask for the information from the patient. Like what this person knows about 
their pain, how long is it going, why does that happening, what this person thinks about 
the pain and how bad it” P7 
When patients have a prescription, participant pharmacists would try to check the 
prescriptions for appropriateness, identify possible drug interactions, monitor patients for 
side effects and suggest appropriate alternatives for prescription problems to physicians 
when needed. 
“I prefer to ask some questions before filling anything, so it depends on what type of, 
again, disease states that they say they have and what they’re using it for.” P5 
 
“This person has been on another prescription and doctor prescribed something that may 
cause a problem when it’s combined with one of the existing prescriptions.” P7 
 
“Resolving a lot of drug interactions that pop up all of the time. Screening for what’s 
significant, what’s not.” P2 
Furthermore, pharmacists felt that they play a significant role in consulting and educating 
patients about pain management. This includes educating patients face to face about pain, 
medications and non-drug measures such as keeping a pain diary, lifestyle changes, or by 
referring them to available public resources for pain management such as websites. 
“We explain to them that their pain levels are not going to be zero, and that you’re going 
to have to live with a little bit of pain.” P3 
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“I’ll give people websites such as Headspace and MoodGym, like the app. HeadSpace has 
some very interesting things, MoodGym in an Australian website that several, like a 
psychologist and a psychiatrist, that have recommended it at meetings that I go to for 
pharmacists.” P5 
While trying to help patients with their pain, pharmacists also try to control opioid abuse. 
As elaborated by one study participant, pharmacists felt they were considered as gatekeepers 
for opioid abuse. If they do their job properly, they can protect society against opioid abuse 
and addiction. 
“We’re being asked to be the gatekeepers and making sure that we’re dispensing 
properly.” P3 
2. Opioids 
To obtain a better understanding of pharmacists’ challenges and concerns about patients 
with chronic pain, I asked pharmacists about their main concerns and difficulties in dealing 
with patients with chronic pain and dispensing their medications. All participant 
pharmacists described opioids as their main concern about patients with chronic pain. In all 
interviews, pharmacists frequently had experienced difficulties with opioid prescription and 
in dealing with patient using opioids. Their main concerns about opioid use can be 
categorized into three sub themes; 1. misuse (addiction, diversion) 2. inadequate monitoring 
3. inappropriate use of medications or resources. 
2.1 Sub-theme: Misuse (addiction and diversion) 
Addiction is defined as compulsive need for and use of a habit-forming substance (such as 
opioids, nicotine, or alcohol) characterized by tolerance and by well-defined physiological 
symptoms upon withdrawal (147). Diversion is defined as a medical and legal concept 
involving the transfer of any legally prescribed controlled substance from the individual for 
whom it was prescribed to another person for any illicit use (32, 33). Based on the coded 
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data, risk of misuse (addiction and diversion) were the most frequently stated concerns of 
pharmacists about opioid use. A participant said: 
“They have two major side effects, which is addiction and diversion. I mean obviously, 
there is a lot of talk about addiction and opioid misuse and opioid abuse. Which obviously 
needs to be addressed, I just hope, and often I don’t see that the needs of chronic pain 
patients are fully addressed at the same time.” P1 
Almost all participants had witnessed situations when their patients had become addicted or 
abused prescription opioids. Some had observed situations in which their customers sold 
prescribed opioid medications in the street. This potential for abuse was associated with a 
huge sense of responsibility to minimize the risk of abuse. In their perspective, as 
gatekeepers for opioid use, pharmacists are responsible for the health of their customers and 
society. However, the participants felt that fear of abuse should not leave patients in pain; 
they were motivated to exercise caution to check the appropriateness of medications to 
prevent opioid abuse. 
“We’re being asked to be the gatekeepers and making sure that we’re dispensing 
properly.” P3 
“We do our due diligence and try to make sure that it’s being used for appropriate 
reasons.” P4 
I do have patients who explain to me the process of how other patients extract the 
fentanyl from the patches.” P3 
 
“Addiction doesn’t mean that they should be left in pain you know. I mean obviously, 
there is a lot of talk about addiction and opioid misuse and opioid abuse. Which obviously 
needs to be addressed, I just hope, and often I don’t see that the needs of chronic pain 
patients are fully addressed at the same time.” P1 
Participant pharmacists also had concerns about the potential risk of abuse to the health of 
society, since these medications could affect patients’ family members or other people in 
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the society by being sold as street drugs. I found two main dimensions about their concerns 
about the society, first, the people whose health may be endangered by being exposed to 
opioids and secondly, the healthcare budget that is being spent on opioids. 
“The biggest concern that I usually have. And just, once again, it ties into the safety of the 
community — it makes them a target.” P4 
 
“Always the potential for abuse or misuse by anyone and if not by the patient, who else is 
in the home that could abuse.” P1 
 
“There’s no black-market for blood pressure medication, but there is a black-market for 
opioid medication. It’s not that they pay for it out-of-pocket, it’s government-sponsored. 
And so, for me, that’s the biggest thing that I think about over time.” P4 
 
“I don’t know if you’ve read about Smarties-Parties, but kids are stealing the painkillers 
from the medicine cabinet of their family and friends, and they throw them in a bowl and 
you take one. And it’s called a Smarties-Party. And that’s extremely dangerous.” P5 
There are two major sources to access opioids, OTC opioids, mainly Tylenol#1 consisting 
of 325mg acetaminophen, caffeine and 8mg codeine. Many pharmacists believed that this 
is an easy but not healthy way to access opioids. Addicted patients could use Tylenol#1 as 
an easy-to-access source of opioids. However, this can be unsafe since the acetaminophen 
content can be hepato-toxic in doses greater than 4grams per day. Although pharmacists try 
to limit the sales of OTC opioids, according to some participants, this is not an easy job 
since the demand for OTC opioids is high and limiting sales can lead to manager 
dissatisfaction, especially when not all pharmacies have the same motivation and policy for 
limiting the sales of OTC opioids. This can lead to a loss of revenue when patients go to the 
other pharmacies that are willing to sell OTC opioids without limitations in quantity. 
“Over-the-counter codeine sales, I have a big problem with it. Because it is pain 
management, but very often it’s a maintenance of addiction too. You know they can’t get 
over the narcotic because they are already addicted and they are very uncomfortably not 
to be taking those medications regularly.” P7  
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“I don’t know why this province does nothing about Tylenol ones. I sent you a note about 
that. I mean every store has people addicted to Tylenol ones, I’m sure, has people that 
come in regularly and buy 100 or 200 Tylenol ones. We are not doing well. I think Tylenol 
one should be monitored on the ONMS, and that way if somebody is getting more than 
the safe amount of Tylenol, then at least you can do something about it.” P4 
 
“I’ve talked to other pharmacists in Ottawa and they give out huge amounts of Tylenol 
one and often they’re positive that the patient is getting more at another pharmacy.” P5 
Prescriptions are the other source of access to opioids. Participant pharmacists believed that 
some physicians prescribed opioids in large amounts without concern for abuse. 
“Like when one 3 months of oxycocet and the patient is taking every 6 hours as needed 
and they’re getting 400 tablets. This is where I’m a little bit more concerned.” P3 
 
“If such high quantities are being prescribed. So, that for me is the biggest concern — like 
they’re so used to getting like 200 Oxycocet. Like I would never know for instance, maybe 
the patient only takes 100 in real-life and the rest of the 100 is being sold on the street.” 
P4 
 
“A lot of patients are getting 120 or more Tylenol 3s a month! You know, for chronic pain, 
and I’m thinking.” P5 
 
“We even had people where the staff in the pharmacy said “they’re selling them.” P5 
2.2 Subtheme: Inadequate monitoring 
Inadequate monitoring is believed by pharmacists to stem from several factors. Participant 
pharmacists thought that there is inadequate record keeping in physicians’ offices, which 
makes it more difficult for physicians who are unable or do not spend time to check the 
prescription records of patients taking opioids. Pharmacists believed that the 5 to 10-minute 
visit time allocated to patients by most physicians is insufficient for thorough review of the 
medical records of patients. Second, some pharmacists felt that physicians are pressured by 
addicted patients to prescribe opioids. These patients persuade prescribers by insisting on 
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having opioids prescribed for their pain with excuses such as travel or even threatening 
prescribers. According to one pharmacist, the other issue that may persuade physicians to 
write opioid prescriptions for addicted patients is that opioids are the only available 
therapeutic option to manage their pain. Other therapeutic options such as non-opioid 
medications (Lyrica, topiramate) or non- drug interventions such as physiotherapy are not 
covered by the government and are expensive for uninsured patients. This topic will be 
discussed more under the topic of “Inappropriate use of medications and resources.” 
“The biggest problem that I find is the physician’s lack of a proper record about the 
frequency of the medication.” P7 
 
“I had one doctor tell me, he had a patient who was in her 80s and he said “she’s going to 
fire me, as a doctor! She’s been my patient for over 40 years and she threatened to fire 
me!” So, you know, I think that doctors do get a problem with their patients and they 
don’t want to upset them either you know, if you have a nice guy as a doctor.” P5 
Pharmacists believed that physicians should be able or spend time to check records of 
opioids prescribed to their patients. This becomes critical when patients use walk-in clinics 
to obtain opioids in addition to those prescribed by their primary physician. This seems to 
be an effective strategy to get more prescription opioids. When patients use opioids faster 
than prescribed and the pharmacy refuses early fillings, patients ask physicians at walk-in 
clinic for prescriptions. 
“We’re trying to make sure that they’re getting the refills on time, but suddenly these 
patients, either they go to a walk-in clinic and they ask for extra pain meds or they go to 
their physician and they come up a story about how they want to leave or go away or 
whatever story, whatever excuse. Whether they lost them, or they got stolen, and there’s 
really no further due process about dispensing.” P3 
Study participants also thought that patients who are using or are projected to use opioids, 
should be assessed more accurately for the potential risk of abuse. Some pharmacist 
interviewees told me that although there are tools to assess the risk of abuse, many family 
physicians do not use these tools, and even if it is used, the patient may not answer honestly. 
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For instance, as three participants mentioned, it is probable that patients would conceal that 
they or a family member have or had a history of addiction. 
“I don’t think we’re very systematic in assessing for addiction. The pain specialist that I 
work with, she is systematic — she does that with every patient — but family doctors are 
not.” P9 
 
“They could be not telling you the truth. For example, when you say family history of 
addiction, which has a big scoring component, they could be lying about that or not 
telling you the truth, right.” P3 
As gatekeepers, pharmacists try to limit the risk of abuse; 
“We do our due diligence and try to make sure that it’s being used for appropriate 
reasons. We do our due diligence, and we know that if we suspect anything then we’ll 
contact the appropriate authorities and things like that.” P4 
But participant pharmacists believed that there are several barriers to the prevention of abuse 
and forgeries. These include lack of a proper communication system between pharmacists 
and physicians to easily share patient information and the lack of incentives for pharmacists 
to routinely perform patient assessment, monitoring, and documentation. One pharmacist 
felt that in comparison to other prescriptions, chronic pain and opioid prescriptions are very 
labor intensive, and pharmacists are not paid and for the extra time they have to spend for 
such monitoring and documentations. 
 “We have a very poor system of communicating with other pharmacists. Because you 
hope that they read your red alert note and they don’t always read it.” P5 
 
“Why do we expect community pharmacists to work free of charge?” P1 
Another barrier in monitoring is fiscal issues. As two pharmacists mentioned that financial 
issues are an important problem, since selling medications is the sole source of income in 
community pharmacies. A pharmacist who had tried to refuse the sale of large amounts of 
an OTC opioid to a patient, was approached by the pharmacy manager and was told: 
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“Now this patient will approach the nearby pharmacy and will buy whatever he wants, 
but we missed our customer” P10 
On another occasion, a pharmacist who had become suspicious of a doctor prescribing large 
amounts of opioids for a long time to a patient who was the physician’s family member, 
approached the pharmacy manager about her intention to report this as misconduct, the 
manager opposed her explaining that the physician’s prescriptions made up a significant 
portion of their revenue. 
“I want to report this doctor to the CPSO, this is not right. You’ve been filling this med for 
a long time for this lady, and it’s her husband! They have the same last name. You know, 
this is not right.” The manager replied “this doctor gives us 11% of our prescriptions, we’ll 
lose business if you report him.” P5 
She insisted on reporting this violation and the physician gave up her license. After a short 
time, she lost her job because she had reported the misconduct. 
“I was told you’re not welcome to stay at this store, not too long later I was fired 
essentially.” P5 
While most pharmacists in our study were concerned about opioid abuse and inadequate 
monitoring before prescribing, and were focused on improving the assessment and 
monitoring measures to reduce the risk of abuse, two pharmacists proposed that access to 
opioids and/or the number of prescribed opioids should be limited. They believed that 
limiting access to opioids can reduce the risk of abuse. As examples, only authorize 
physicians and pharmacists who have extra training in pain management and opioids to 
prescribe or dispense opioids, limiting prescribing practices to specific medical centers, or 
limiting the number of opioids that can be prescribed each prescription. Furthermore, walk-
in clinics should have a policy which restricts prescribing opioids to short durations only. 
“I mean ultimately; they should be a little stricter on a lot of prescribers. Some products, I 
feel, should only be available in the hospital - let alone, like you shouldn’t be able to do 
exceptional access unless there’s like definitive proof.” P4 
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“Walk-in clinics really need to step away from prescribing chronic pain medications, 
unless they do it for a very, very limited period of time.” P3 
 
 “The other one is limiting quantities; I think that’s extremely important. Physicians need 
to be more aware of quantities. Physicians need to be more aware of refill frequency.” P3 
 
 “I think that two weeks to a month, maximum! I think that’s what these patients should 
be prescribed. Sometimes I’m more concerned with the actual quantities that’s being 
given, rather than the dosage. Like when one 3 months of Oxycocet and the patient is 
taking every 6 hours as needed and they’re getting 400 tablets. This is where I’m a little 
bit more concerned.” P3 
 
“Like don’t get me wrong, we don’t mind releasing the medication early, but there needs 
to be some documentation on the prescription as to why you’re doing that. This is your 
job as a prescriber, to document why you’re allowing that. It shouldn’t be my job as a 
pharmacist to try and chase you for half a day as to why you’re doing this.” P3 
2.3 Sub-theme: Inappropriate use of medications and resources 
Almost all study participants were concerned about the inappropriate use of medications 
and resources for treatment of chronic pain. By analyzing the data, two parameters emerged 
that play a role in inappropriate use of medications, particularly opioids; realistic 
expectations about chronic pain and its management, and the lack of alternatives for opioids. 
2.3.1 Realistic expectations from chronic pain treatment  
As recognized by the pharmacist participants, the main goal of treatment in chronic pain is 
functionality. Patients should receive education to have realistic expectations about their 
pain. Based on the participants’ experience, most patients do not achieve complete 
resolution of their pain, even with opioid medications. Thus, having realistic expectations 
about chronic pain can lead to more rational use of medications and prevents unnecessary 
exposure to opioids whose side effects may decrease patient functionality. Furthermore, 
inappropriate use of opioids may reduce functionality by producing physical and 
psychological dependence. Hence, one of the aspects of appropriate use of medications in 
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chronic pain is setting expectation for treatment. Participants believed this can be obtained 
by educating patients about chronic pain and the goals of treatment. 
“Person who is like “just give me a pill, if I get the magic pill then I’m good”. And it’s going 
to be harder for that person who is looking for the magic pill and not ready to do the 
other things.” P1 
 
“The ultimate goal here is not to get rid of the pain completely, but to reduce it to a level 
where functionality on day-to-day activities become possible.” P3 
“Are you moving more? Are you doing more in your day? No? Do you think this is really 
giving you much more in your quality of life and you being able to participate? If you’re 
not improving function, then it’s not worth having.” P1 
 
“We explain to them that their pain levels are not going to be zero, and that you’re going 
to have to live with a little bit of pain.” P3 
However, some study participants thought that there is a huge gap in education for patients 
about the proper use of medications and opioids. 
“I don’t think that we do a good job of educating patients about, you know, opioids don’t 
work for everybody, they don’t work for every pain problem, and the goal of treatment is 
to make them more functional — so if opioids don’t help them reach that goal then we 
have to stop them because they do have significant side effects.” P9 
2.3.2 Lack of alternatives for opioids 
The second reason for improper use of therapeutic options gleaned from the data is that 
non-opioid medications and interventions are not used prevalently. 
“I think that we’re not doing well in pain management of people with chronic pain who 
are not on opioids, we’re not doing well at all.” P5 
There are many non-opioid medications that have significant efficacy in alleviating chronic 
pain with more favorable adverse effects profiles, but are not prescribed effectively or 
adequately in daily practice. This topic was raised by one of the participants and I tried to 
investigate this idea in subsequent interviews. Participants had similar ideas and suggested 
that these medications were less-prescribed because these medications are not covered by 
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the government or insurances. According to study participants, governments have a large 
budget for opioids but not for other medicinal or interventional therapeutic options that 
might be equally effective with a better safety and adverse effects profile. 
“I think, to encourage opioids maybe, was a mistake in people with chronic pain. I mean 
people that are in pain where it’s not going to go away and it’s not fibromyalgia — don’t 
get me wrong, I think opioids have to be used for chronic pain — but I no longer believe 
that they are necessarily the best choice” P5 
 
“The government needs to look into covering, for example, medications like Topamax, 
lamotrigine; they should look into covering other non-opioid treatments that right now 
they don’t cover. Like Topamax and lamotrigine, they are only covered for epilepsy, but 
they have a lot of uses in chronic pain.” P3 
It is mentioned that patients generally cannot afford these therapeutic options, particularly 
when they might be disabled by chronic pain at least to some extent. 
“Somebody who hasn’t worked in five years because of chronic pain, can’t afford to do 
those things.” P3 
 
“Let’s say if we’ve tried Cymbalta or Lyrica, and they’re not anymore functional on it, 
they’re quite happy to stop it. It is very easy to say “I don’t think this is really helping you 
that much and you seem to agree so we’re just going to stop it”. And people agree with 
that. But when you have that same conversation about opioids, for some reason, people 
are much more resistant to giving up their opioids.” P9 
 
“So, a patient is on a fixed dosage and suddenly they’re asking for more and for more. 
We’ll tend to review the whole condition and see what other type of other medication 
categories we can introduce, rather than escalating the dose of the opioid.” P3 
 
“Government should actually do a little bit of a better job approving or actually covering 
non-opioid therapy.” P3 
 
“Getting massage therapies and things but people can’t afford it! They can’t afford the 
psychological counselling and cognitive-behavioral therapy that might be useful.” P5 
50 
 
One pharmacist speculated that in real practice, physicians have very few options aside from 
opioids. Non-opioid medications such as Lyrica and interventional options such as 
physiotherapy are not covered by government or insurance. 
2.3.3 Sub-theme: The need for comprehensive approach 
Study participants frequently spoke of the physical, psychosocial, vocational, and social 
aspects of chronic pain. They believed that treatment of chronic pain goes beyond 
prescribing medications. Chronic pain and its associated health conditions such as 
depression and anxiety that impact patients’ lives should be addressed by variety of 
healthcare professionals including physiotherapists, psychotherapists, nurses, social 
workers, and occupational therapists. 
“I think that it’s something that needs to be addressed, perhaps holistically — more than 
just prescribing pain-killers.” P8 
 
“We’re dealing with a full spectrum of symptoms from anxiety, from depression, from 
even organic effects on blood pressure and sugar control.” P9 
 
“I think that we need not just pharmacists but other healthcare professionals and patients 
and society in general to recognize that chronic pain management is not just drugs. 
There’s a huge role for psychological treatment, and physical treatments, not just 
physiotherapy but things like tai chi, yoga, mindfulness space stress reduction — those 
sorts of things.” P9 
 
“You need to be looking at non-drug methods, you need to be looking at cognitive-
behavioral therapy, meditation, you need to be looking at a lot of different things that 
pharmacists are not familiar with.” P5 
Although the necessity of a comprehensive approach was clear to participants, they believed 
that this necessitates the presence of medical centers in which healthcare professionals can 
work together to serve patients with chronic pain. However, few centers in Ontario offer 
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specialized and comprehensive services to patients with chronic pain and many patients are 
on long waiting lists for pain management clinics. 
“Like we don’t have that many pain management clinics — it takes over a year to get into 
one in Ottawa, and I really, I strongly feel that for good pain management, you need a 
team approach.” P5 
Responses to my question “when chronic pain is quite prevalent (17%) in Canada, why is 
there not enough infrastructure to serve patients with chronic pain while other chronic 
diseases such as diabetes have better treatment facilities?” are as follows; 
“I think if you’re going to set up a chronic pain program, you do need to have dedicated 
funding. Or you need to say to your healthcare practitioners, for example, if you have a 
social worker who is — for example we have a social worker here, and she’s wonderful. 
But she, right now, her next available appointment is in January.” P9 
 
 “So, I actually am not sure. I’m not sure if it’s because you know, diabetes has the 
Canadian Diabetes Association and they lobby and they raise money for research and you 
know, cancer obviously has the Canadian Cancer society and they have huge fundraising 
things. So, I don’t know. It might be that chronic pain is a very heterogeneous condition — 
you know it comes from many different.” P9 
 
“Treatment is complex and multifactorial and drugs are a small part of a successful 
treatment plan and the other parts are kind of expensive — things like physio, 
occupational therapy — you know. And it might, it’s kind of in a way, it’s hard to measure 
too. So, you know, like it’s easy for the province to look at wait times for hip replacement, 
although I guess they could look at wait times for chronic pain clinics this is like they do 
not open a can of worms.” P9 
They believed that while chronic pain as a multi-dimensional health condition needs a 
multi-modal approach by collaboration of several health care providers, there is 
insufficient budget allocated by the government to cover multi-modal collaborative care 
services to patients. 
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3. Patients’ concerns 
This theme describes the main patient concerns from the pharmacists’ point of view. From 
their perspective, patients have three major concerns; lack (inadequate) of pain control, lack 
of support, and fear of addiction. 
3.1 Sub-theme: Inadequate pain control 
The most distressing part of chronic pain to patients is inadequate pain control, which is 
intertwined with the chronicity of pain. All people experience episodes of acute pain that 
disappears over a short period of time, but in chronic pain, the problem stems from long-
lasting uncontrollable pain. Uncontrolled pain affects patients’ mood Pharmacists in this 
study believed that realizing that they will live with a significant level of pain is an 
unpleasant agitating experience to the patients. 
“If the pain is new, then very often, the patient is concerned about being not normal.”    
P7 
 
“I’m anxious, guess what’s going to happen to my chronic pain. I’m anxious, I’m worried, 
my body is tense. I don’t sleep as well. Pain is impacted.” P1 
 
“They want to know what they are; they have an anxiety because having pain is not 
normal for them. They don’t know if it’s good or bad. So, that’s if it’s a new pain. But if it’s 
not a new pain and they have been having pain for a long time, then their first mention — 
it’s inconveniencing them.” P7 
Participants felt this experience becomes even worse when long-term uncontrollable pain 
affects patients’ functionality and quality of life. Pain prevents them from working and with 
lower income, they cannot afford treatment and medication expenses. This keeps them stuck 
in pain. The quality of life ultimately will be affected. 
The person says “I’m stuck with this for life and it’s not doing it. P8 
 
They have many concerns, you know, stemming from their pain. Not just that their pain is 
not controlled, but that they cannot function and you know, have a good quality of life. P9 
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“I believe that the main concern is to be able to be pain-free or at least lessen the pain so 
that they can go on and do their own daily routine. Once they can manage that one, like 
they can do their job or life or studies or whatever, I believe that they’re fine with it, as 
long as they can be pain-free and their quality of life be back to normal.” P6 
Even when the pain can be controlled by medication, the patients’ functionality can be 
impaired by side effects such as drowsiness and confusion.  This emphasizes the importance 
of using an appropriate strategy for use of medications with the ultimate goal of maintaining 
the patients’ functionality. 
They don’t want to feel drowsy or foggy. Or one lady said that “I feel spacey on these 
meds, I feel kind of spaced out”. You know, they don’t want to lose their ability to think 
quickly, you know. So, that seems to worry my patients are legitimate pain med users. P5 
3.2 Sub-theme: Lack of support 
The second topic that emerged under patient concern is the lack of support, particularly 
emotional support from health care providers, family members and financial support from 
the government. 
3.2.1 Lack of emotional support 
Participants believed that since pain is a subjective feeling, it may not be well-understood 
by those who have not experienced pain, and in particular, chronic pain. The subjective 
characteristic of pain can put patients in an emotional state of being not believed and 
understood. These patients need to be heard and validated by family members and friends. 
Aside from expecting their health care providers to do their best to control their pain, they 
would like their concerns to be heard by them. They expect society to believe and validate 
their pain. This is of importance especially when functionality is impaired by pain and not 
understood by others. 
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“I think there is something about being seen, being heard, being understood, being 
validated, and having a place where they are believed. And some days I think that that’s 
the therapy and that’s therapeutic in and of itself.” P1 
As a pharmacist explained, when patients feel that they are not believed by the society, 
they may extrapolate this perception to their health care providers. 
Lots of these patients are concerned with how they feel when they approach their 
healthcare provider or their pharmacist for their prescriptions. P3 
3.2.2 Lack of support by health care system 
Pharmacist participants also believed that patients with chronic pain did not have adequate 
support from the government and to be specific, the health care system. Patients have to 
wait for a long time before they can visit pain specialists. In several interviews, interviewees 
mentioned waiting times of about two years that looked unbelievable to me at first, but has 
long been a reality in the world of patients with chronic pain. Having patients being left by 
their debilitating pain on long waiting lists makes patients feels abandoned by the 
government. 
“I feel bad for them, because there’s a lack of services to address their problem.” P9 
“I guess I’m just glad that I don’t have chronic pain. Because there’s — the wait time for 
specialist assessment is very long. In Ottawa, on average, a patient in Ottawa can expect 
to wait at least two years to see a pain specialist.” P9 
In addition to long waiting lists for patients to access chronic pain health services, 
participants felt that there is a lack of coverage for medications and alternative treatments 
such as physiotherapy and psychotherapy for chronic pain. As discussed above, many 
alternative medications for chronic pain -despite better safety and adverse effects profile 
that can be good substitutes for opioids - are not covered by the government or insurances. 
“So, that’s one thing. And depending on their insurance coverage — drug insurance 
coverage — they may not have money to pay for pain medications. So, you know, we try 
to help them with that through, we try and arrange drug coverage — drug insurance — 
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through Trillium drug program, and if that doesn’t work then we try to access 
compassionate drug programs to get medication. But of course, there are no 
compassionate drug programs for opioids.” P9 
 
“So, you know, like it’s easy for the province to look at wait times for hip replacement, 
although I guess they could look at wait times for chronic pain clinics this is like they do 
not open a can of worms.” P9 
3.3 Sub-theme: Addiction 
Interestingly, study participants believed that many patients have similar concerns about 
addiction. In the perspective of the participant pharmacists, many patients are worried about 
addiction and diversion and this fear of taking opioids may play a role in inadequate control 
of pain. Many patients with opioid prescriptions are concerned about having to take opioids 
for life mainly due to the fear of addiction. This fear seems to be more significant among 
older patients. In contrast, there are patients who are so fed up with pain that they just want 
something to treat it. 
“Some patients don’t want to use opioids because they have heard that it is addicting.” 
P4 
The other concern is the stigma of addiction. Some patients are concerned about how they 
would be judged by other people such as their family members and colleagues. According 
to one participant, for some people, taking opioids for pain relief is equal to addiction and 
addiction is considered sinful by their community. 
“I don’t like people knowing that I’m on these medications.” P1 
“They instantly connect narcotic with addiction and now addiction means behavior for 
them. Basically, in this situation. And they feel that being a “drug addict” and they will 
become “drug addicts” and so they treat it like a sin, because being dependent on 
narcotics is still like a sin for some people still. So, they do not want to be cleaning up by 
being addicted to narcotics so they will refuse.” P7 
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In response, participating pharmacists try to address patients’ concern about addiction and 
discuss the possibility of addiction and the benefits of controlling the pain. Furthermore, 
pharmacists, especially in family health teams, try to propose alternatives for opioid 
medications. However as discussed before, a significant number of patients cannot afford 
the alternatives. 
“I don’t want to be hooked,” “I don’t want to be dependent,” “I don’t want to be addicted 
to these medications.” For those patients, we look at alternatives. So, we’ll look at nerve-
altering agents, we’ll look at anti-inflammatories, we look at newer generation anti-
epileptics, we’ll look at cortisol injections. 
The other concern worth mentioning is the safety issue, safety in terms of keeping opioids 
out of reach of potential abusers in the family and the neighborhood. 
“Partially because of safety, like just because maybe their neighborhood is a little rougher 
— so they have to be careful. Because you know, there is a street value for it. So, people 
have to worry about that.” P4 
 
“I don’t know if you’ve read about Smarties-Parties, but kids are stealing the painkillers 
from the medicine cabinet of their family and friends, and they throw them in a bowl and 
you take one. And it’s called a Smarties-Party. And that’s extremely dangerous.” P5 
4. Pharmacists communication with physicians 
Almost all pharmacists in this study stated that they had good communications with 
physicians. Everyone would prefer to communicate with physicians by fax except one 
family health team pharmacist who preferred face-to-face communication. The main 
reasons for contacting a physician were errors in prescription, administrative, legal issues 
(ordering refills for opioids, which is illegal), incorrect amounts of medications, typos, 
physician signatures, drug interactions, opioid dose conversions, and physicians inquiring 
for availability of medications and available dosage forms in the market. 
“Physicians and pharmacists, they need to work closely together in terms of chronic pain 
management, because not only are we dealing with efficacy, but there are safety issues 
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that are not only related to the patient, but to the whole community. I mean these drugs 
are making it to the streets, and it is just a big problem.” P3  
 
“The mechanics of writing a narcotic or an opioid prescription, part-fills.” P8 
 
“They haven’t signed the prescription or they haven’t written it properly according to the 
prescribing rules for narcotics or opioids, then those are the main topics about legal.” P6 
 
“What’s the starting dose for this type of medicine” or “what is available in your 
pharmacy, I want to prescribe something like this but I don’t know what’s available.” P7 
4.1 Sub-theme: Barriers to communication 
Older participants who had more than 20 years of experience believed that communication 
between pharmacists and physicians has improved over the last 20 years, and all 
participating pharmacists had positive feedback from their communication with physicians, 
although they thought that barriers for effective communication with physicians still exist. 
“So, pharmacists are often bound by little picky details that they have to ensure that are 
done, and physicians may not be aware of that. And with a doctor who is in a high-stress 
area — and pharmacists are too — they won’t realize why they are getting these 
messages and why these things need to be changed.” P1 
Many pharmacists believed physicians are not very accessible, particularly those who work 
in hospitals and whose contact information is unavailable. This is of importance when 
pharmacists must contact the prescriber because a prescription has some items missing. In 
my interviews, I realized that some hospitals addressed this problem by having another 
doctor look at the prescription if the prescribing doctor had gone home. 
“In the hospital, a lot of doctors don’t necessarily work every day of the week — they may 
only pop-in like twice a week. So, if it’s prescribed, and unfortunately, we can’t get a hold 
of the doctor, then that’s honestly the biggest issue I would say.” P4 
Some physicians are uncooperative. Although this occurs infrequently, by asking probing 
questions I discovered several characteristics in common among non-cooperative 
physicians. It seems that older physicians are less communicative and receptive to 
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pharmacists’ comments. Those physicians who graduated from training programs with a 
team-focused approach are more communicative and receptive to pharmacists’ suggestions. 
The personality of the physician also has a role; some people are less communicative by 
nature. According to one of the participating pharmacists, physicians who are empathetic 
and spend more time for their patients are more likely to be receptive to pharmacists’ 
comments. 
“Some doctors seem to get deeply offended when you make a suggestion and other 
doctors send you a smiley face and a thank-you.” P5 
 
“I’ve found that the majority of the younger physicians, with the new system that they’re 
coming out — like they’re graduating and they are used to having teamwork with 
pharmacists and with other healthcare, so they do actually respect it more.” P6 
 
“I’ve sort of learned to figure out, who is this person behind the MD? What do they like? 
What’s going to work for them, and what do I bring that can help and support them.” P1 
 
“If they are an empathetic doctor who gives each patient more than their 5 or 10 minutes, 
then usually they’re willing to accept suggestions. But if they’re a “you get 5 minutes and 
you’re out the door/ one problem doctor”, then I usually find that they are not responsive 
to any suggestions from a pharmacist.” P5 
4.2 Sub-theme: How to improve communication with physicians 
Many pharmacists were of the opinion that trust between pharmacists and physicians plays 
a pivotal role in their communication with physicians. In my interviews with pharmacists, I 
detected three common elements among pharmacists who had stablished good 
communications with physicians; 1- trust develops over time. 2- making physicians familiar 
with profession of pharmacy and their scope of practice and 3-  improving knowledge and 
skills to provide physicians with appropriate recommendations. As a first step in building 
trust, pharmacists should make face-to-face and social interactions with physicians. This 
can be as simple as introducing themselves to physicians or participating in joint career 
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events with physicians. Some physicians are not familiar with the scope of practice of 
pharmacists. Such communications make physicians more familiar with pharmacists and 
their scope of practice. 
“So, pharmacists are often bound by little picky details that they have to ensure that are 
done, and physicians may not be aware of that. And with a doctor who is in a high-stress 
area — and pharmacists are too — they won’t realize why they are getting these 
messages and why these things need to be changed.” P1 
The second element in building trust is improving clinical skills and doing a thorough 
research of references to provide them with appropriate recommendations when needed. 
Pharmacists should follow certain criteria to have effective communications with 
physicians. Suggestions should be made based on references, offering options and 
alternatives in recommendations for problem. Providing physicians with correct information 
makes pharmacists credible to collaborating physicians over time. 
“Sometimes when I had done my research before I contacted the physician and those 
times I noticed that I could get better response than when I had no idea what I was 
talking about.” P6 
 
“So, honestly the big thing is trust. So, the staff docs have all known me for years, and the 
residents have heard from the staff docs and the nurses that I know what I’m doing, 
basically. So, there is a trust there. And that does take time to, definitely takes time to 
develop.” P9 
 
“My concern with pharmacists is that they do make recommendations without providing 
an alternative we can’t just paint the problem in a broad statement and send it to the 
physician to deal with. I don’t think they appreciate that. They appreciate suggestions, 
and they appreciate alternatives. So, if you do have a problem with anything that the 
physician prescribes, don’t just limit it to the problem.” P3 
 
“We don’t get our point across, we don’t give the references, we don’t give doctors 
options frequently. Like I look at other peoples’ faxes and I think my god why didn’t they 
give the doctor some suggestions at least as to what they can do instead you know.” P5 
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In considering the several tasks and responsibilities that both physicians and pharmacists 
deal with in their daily practice, one pharmacist stated that effective communication can 
help avoid misunderstandings. This is more important in community pharmacies where 
most communications are made by fax or short phone calls. 
“I think that there is very little training on how to properly communicate with a doctor by 
fax. It’s difficult, you know, you cannot get a hold of a doctor by phone ordinarily. And 
usually they’re in a big hurry — it’s very hard to explain anything in detail over the phone. 
So, you put it in a fax and hope that they get it, but it’s not an easy situation for 
pharmacists. I find that I don’t have the skill — because we’re used to typing things “take 
1 tablet, 4 times a day, so we’re used to typing things short and sweet. It’s difficult when 
you have to type something to a doctor and you have to put it in a manner that’s simple, 
easy to understand and non-threatening.” P5 
5. Knowledge gaps 
The final component of interview consisted of participants describing knowledge and 
educational requirements to improve pharmacists’ skills to provide better service to patients 
with chronic pain. Improving knowledge and skills in pain management, legal issues, and 
communication with prescriber and patients were elaborated by participant pharmacists. 
5.1 Sub-theme: Knowledge about chronic pain  
Adequate knowledge about pain management enables pharmacists to help patients to cope 
better with their pain and associated health difficulties. Up-to-date knowledge is a 
cornerstone in pain management, helping pharmacists to offer better recommendations to 
physicians and patients. However, almost all pharmacist participants believed that they 
needed more training for pain management. They think pharmacists need training in several 
areas ranging from pain assessment and pharmacologic treatments to non-pharmacologic 
treatments and communication skills. From their perspective, practicing pharmacists have 
varying levels of knowledge about pain management, including knowledge about medical 
and non-medical treatments. This discrepancy between pharmacists can lead to opposing 
recommendations to patients, adversely affecting pharmacists’ credibility and patients’ trust 
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of pharmacists. In the perspective of some participants, this inconsistency might arise from 
different levels of education about pain in school and the date of graduation from pharmacy 
school. Pharmacist participants believe there is a difference in knowledge between 
pharmacists who graduated within the last few years compared to those who graduated 10 
or 20 years ago. This knowledge gap can be covered by continuous education programs. 
“We learn it all in school, but some of us graduate 2 years ago, some 10 years ago, some 
20, some 30. So, a refresher would be good to boost that confidence and to do that.” P2 
 
“Just in case you know, people ask a question, and go to another pharmacy down the 
street — which often happens — and somebody says to them something completely 
different. And that doesn’t look as professional.” P4 
 
“If you have a very good knowledge of pain and the management, then it will definitely 
help you to communicate better with physicians in terms of also recommending 
alternatives or you have a better idea about the dosing and other alternative options as 
well. So, it’s a combination of both — the knowledge and the communication together.” 
P6 
 
“I feel that we should have a lot more training in pain management. If so many people 
have pain, we should be getting a lot more education on how to help them with their pain 
than we are getting.” P5 
 
“Also, if they are bringing their situation to you with a better knowledge and with their 
training and everything, you can also reduce their anxiety, reduce their wait times, their 
interruptions, and therefore, they would have a better quality of life and better pain 
management.” P6 
5.2 Sub-theme: Knowledge about legal issues 
Pharmacists think they also need more knowledge and training in legal issues associated 
with narcotics. Many pharmacists are not confident in areas such as how to react to forgeries 
or how to report misconduct of healthcare professionals to authorities. 
“Pharmacists aren’t taught to recognize suspicious prescribing methods, and we aren’t 
taught what to do about it.” P5 
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 “Like if someone came in, how would you catch it or how would you respond. Because no 
one taught us, like do I call the police, do I — like even now, to this day I don’t know if I’m 
legally obliged to call the police if we catch them. I would think yes, but the thing is how 
would you do so. Like you need to run through some scenarios, because when it actually 
does happen to you in real-life.” P4 
 
“A review of the jurisprudence, and then a review of the clinical aspects of pain 
management.” P8 
5.3 Sub-theme: Communicational skills 
Pharmacists communicate with both physicians and patients. Pharmacist participants 
believe communicational skills affect their relationship with patients and physicians. Good 
communication skills help patients to understand consultations and recommendations better. 
Since both pharmacists and physicians are engaged with multiple duties and responsibilities 
in their daily practice and have meager time for communication, communication skills play 
a pivotal role in communicating fast and simple for efficient and timely results. 
“If you communicate better with them (patients), on time, it will help the patient to get 
their medications on time, to properly use them, and also there won’t be any interruption 
between the chronic pain management.” P6 
 
“We didn’t really learn too much on the empathy.” P4 
“I think that there is very little training on how to properly communicate with a doctor by 
fax. It’s difficult, you know, you cannot get a hold of a doctor by phone ordinarily. And 
usually they’re in a big hurry — it’s very hard to explain anything in detail over the phone. 
So, you put it in a fax and hope that they get it, but it’s not an easy situation for 
pharmacists.” P5 
To cover this knowledge gap, some pharmacists suggested short continuing education 
programs including specialized chronic pain workshops or webinars. As a participant 
explained, an effective training program should cover several aspects of chronic pain. 
“Specialized courses. I think that I would like for organizations to have pain physicians 
come and give lectures. I would like to have workshop sessions where you have 
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specialists, you have physicians, you have pharmacists, you have social workers, you have 
addictions specialists coming in and giving different perspectives on chronic pain 
management.” P3 
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Discussion 
The aim of this study was to explore the experience and perceptions of pharmacists about 
chronic pain. Based on our understandings from participants in this study we built a 
theoretical framework (Figure 3) of perceptions and experiences of community 
pharmacists interacting with patients with chronic pain. 
 Our study sample was largely comparable to the population of practicing pharmacists in 
Ontario. (Table 2). Targeted interviews were used to investigate the experience of 
pharmacists in their practice. The findings of the current study demonstrate considerable 
homogeneity in participant pharmacists’ perceptions on the subject. 
The overarching themes derived from the in-depth information provided by the participating 
pharmacists demonstrated their belief that they can play a significant role in providing care 
to patients with chronic pain. They perceived chronic pain as a chronic health problem that 
is inadequately managed. While they empathize with their patients, they were concerned 
about opioid abuse in chronic pain. They propose a comprehensive treatment approach as a 
possible solution for better pain management and reducing the potential of abuse and 
addiction to opioids. In this approach, all health care providers including physicians, 
pharmacists, physiotherapists, psychotherapists and nurses collaborate closely in chronic 
pain management. They had positive feedback about their communication with physicians 
and had suggestions for building relationships for better collaboration. However, they drew 
attention to inadequate communication skills.  
In this chapter, findings of this study are evaluated against the available literature. Although 
there were previous studies that have evaluated some themes of this study separately, in 
other settings, to my best knowledge, this is the first study which provides a detailed frame 
work of pharmacists’ experience providing care to patients with chronic pain. This 
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framework elucidates gaps and presents suggestions to fill the gaps in providing care to 
patients with chronic pain from the perspective of pharmacists. Opioids as a matter of utmost 
concern for pharmacists in providing care to patients with chronic pain 
Canada is the world’s second-largest per capita consumer of opioids (148). It is estimated 
that more than 30 million tablets or patches of high-dose opioids are dispensed in Canada 
annually, despite recommendations to avoid high-dose therapy in most patients (149). 
Gomes et al. (150) reported that rates of opioid-related deaths in Ontario increased by 242% 
between 1991 and 2010, rising from 12.2 deaths per million in 1991 (127 deaths annually) 
to 41.6 deaths per million in 2010 (550 deaths annually). She concludes that this results in 
a number of years lost that exceeds years lost due to alcohol use disorders (18,465 years) 
and pneumonia (18,987 years), and greatly exceeds that from HIV/AIDS (4,929 years) and 
influenza (2,548 years) in Ontario.  
As gatekeepers, this is of huge concern to pharmacists. As will be discussed below, study 
participants believed that adequate monitoring, appropriate use of medications and 
resources and patient education about chronic pain management are of importance in 
effective, safe and sound management of chronic pain which reduce the risk of misuse of 
opioids by patients.  
1. Misuse of opioids  
Most guidelines mention addiction as a potential problem of opioids for pain management 
(28, 151). Participating pharmacists in this study were profoundly concerned about the 
potential for addiction and abuse of these medications. The literature indicates that the 
prevalence of addiction in chronic non-malignant pain patients varies between 0% to 50% 
based on different criteria and clinical settings (152). A review  of  studies  conducted  in  
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tertiary  care  pain  clinics reported  prevalence  between  3%  to  19%  or more (77, 153). 
Thus, the risk of addiction must be considered when initiating long-term opioid treatment. 
Participant pharmacists also perceived a fear of addiction and its stigma as a major patient 
concern especially, in the elderly. Many patients with opioid prescriptions are concerned 
about taking opioids due to the fear of addiction and about how they would be judged by 
other people like their family members and colleagues. This conforms with other studies 
that show patients are concerned about the stigma of opioids (154, 155). Health care 
practitioners can counter this stigma by adopting accurate, nonjudgmental language to 
describe this concern, those it affects, and its therapy with medications (155). As well, in 
the current study, participants explained that they would try to address patients’ concern 
about addiction and discuss the possibility of addiction while weighing the benefits of 
controlling the pain. Furthermore, pharmacists, especially in family health teams, try to 
propose alternatives to opioid medications. 
2. Inadequate monitoring  
The per capita consumption of opioids in Canada is associated with significant numbers of 
premature deaths due to opioids. In a study on deaths due to prescription opioids 
(oxycodone), Dhalla et al. showed that 66.4% of patients were seen by a physician in an 
outpatient setting at least once in the 4 weeks before death (156), implying inadequate 
monitoring for opioids and missed opportunities for the prevention of opioids death. To 
reduce the number of opioid overdose deaths, the Ontario government decided to remove 
sustain release oxycodone (OxyContin) from the Ontario Drug Plan, in the belief that this 
would reduce the number of opioid overdose deaths in the province. While Oxycodone-
related overdoses decreased by 30%, the Centre for Addiction and Mental Health reports 
that overall prescription opioid fatalities increased by 24%. Increases in the number of 
deaths were attributed to other strong opioids that are not subject to the same restrictions as 
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oxycodone (157). This failure in reducing opioids- related deaths signifies the necessity of 
employing comprehensive policies at the level of prescribing and dispensing of these 
medications. As described by pharmacist participants, more precise monitoring for patients 
and prescriptions should be employed. 
In a study about the impact of discontinuation of OxyContin on pain management (144), 
both physician and patients suggested tackling the abuse problem by employing effective 
pain management, monitoring opioid prescribing and individualized pain management 
practices. Other studies and commentaries also provided evidence that detection and control 
of opioid misuse can be achieved in primary care by following such recommendations (158-
160). 
These studies support the results of the present study. In our study, participants championed 
the prevention of opioid abuse by using patient assessment tools, precise documentation, 
and monitoring of patients taking opioids. Real-time electronic databases accessible to 
physicians and pharmacists would make it more difficult for individuals to obtain opioids 
from multiple prescribers or pharmacies and might reduce the risk of drug interactions 
between opioids and other central nervous system depressants (161). Addicted patients have 
access to opioids through OTC medications or at walk-in clinics where secondary physicians 
can prescribe opioids to them. Real-time electronic databases (161) accessible to physicians 
and pharmacists can be a practical approach to limit the access of opioids to patients through 
these methods.  A few participants of the current study also believed that limiting the number 
of prescribed opioids in each prescription and/or limiting prescribing and dispensing of 
opioids to authorized centers and practitioners might be helpful. 
Any signs of aberrant drug behavior should be recognized as soon as possible by 
pharmacists and steps to bring the drug use in control must be taken (152). Detection of 
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addiction in opioid-treated patients should result in referral to specialized treatment facilities 
of pain management. However, patient assessment, precise documentation, and frequent 
monitoring of opioid use by patients is labor-intensive and time-consuming. Considering 
the work load of pharmacists in community pharmacies, and knowing that selling the 
medications is the only source of income in the pharmacies, pharmacists deem this as a 
barrier for controlling the abuse and diversion of opioids. One suggested solution is 
reimbursement for extra work of documentation and monitoring of opioid prescriptions as 
a motive for pharmacists as gatekeepers for opioid medications. 
3. Inappropriate use of medications and resources 
This study identified three parameters in inappropriate utilization of medication and 
resources in chronic pain management: Patient expectations from treatment, inadequate 
access to alternative treatments for opioids and inadequate comprehensive approach for pain 
management. 
3.1 Realistic expectations from chronic pain treatment 
Opioids are used increasingly for chronic non-cancer pain, although there is insufficient data 
to support long-term efficacy and safety of opioids for chronic pain (162). Pharmacists in 
our study indicated that even with opioid medications, patients often do not experience 
complete improvement in their chronic pain. A illustrated in a study on patients with chronic 
pain, because a narrow border exists between pain control and impaired functionality due to 
opioids side effects, unjustified, long-term opioid therapy can significantly be associated 
with reporting of poor self-rated health, being unemployed, higher use of the health care 
system, and a negative influence on the quality of life (163) which is on the contrary to key 
opioid treatment goals including pain relief, improved quality of life and improved 
functional capacity (163). Evidence in the literature shows that function focused 
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expectations about chronic pain management by patients improves their experience of pain 
while reducing the risk of side effects and addiction (39, 164, 165). Noting the literature and 
findings of this study, it can be remarked that having realistic expectations about chronic 
pain by patients can lead to more balanced use of these medications. Realistic patient 
expectation of treatment can be obtained by educating them about characteristics of chronic 
pain, its management and defining pain relief along with functionality as the ultimate 
treatment goal. Employing this approach may prevent overuse of opioids whose side effects 
may decrease patient functionality and quality of life. 
3.2 Lack of insurance coverage for opioid therapeutic alternatives  
A number of non-opioid medications have demonstrated effectiveness in chronic pain 
disorders and their use individually or in combination in the management of chronic pain 
can be advantageous (16, 166). Moreover, non-opioid medications for management of 
chronic pain can produce better functional outcomes than opioids, being outperformed only 
by strong opioids for pain relief (167). Aside from non-opioid medications, there are non-
medication interventions such as physiotherapy whose effectiveness in improving pain and 
functionality in chronic pain has been proven (168-170). 
However, these effective and promising options for opioids are not embraced by physicians. 
Study participants believed this is mainly due to the reality that these therapeutic options 
are not covered by health insurance plans. In the literature, lack of insurance coverage has 
been shown to be one of the core reasons for inappropriate pain management. This issue 
may prevent patient access to costly long-term pain management with its multiple modalities 
(171). Noting that chronic pain is a disabling chronic disease, in which up to 25% of patients 
lose their jobs (172), makes it more urgent for patients to have access to therapeutic options 
for pain management. In situations where there are clinical trials for effectiveness of other 
therapeutic options, these options are worth trying before taking opioids and their associated 
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adverse effects and safety profile. However, this necessitates coverage of these opioids 
therapeutic alternatives by health insurance or government health plans. 
3.3 Comprehensive and multi-disciplinary approach 
Treatment of chronic pain extends beyond prescribing medications. Chronic pain and its 
associated health conditions such as depression and anxiety negatively impact patients’ life 
and such concerns are best addressed by multiple healthcare professionals, including 
physiotherapists, psychotherapists, nurses, social workers and occupational therapists. As 
one participant stated: “The money should go to collaborative work.” The value of a team 
approach to patients with chronic pain has been well-demonstrated (173-176).  The 
beneficial effects of multidisciplinary treatment are not limited to improvements in pain, but 
extended to behavioral variables such as return to work and reduced use of the health care 
system (175). 
Scascighini et al. (177) provide evidence of the higher effectiveness of multidisciplinary 
interventions and conclude that the standard of multidisciplinary programs should be 
internationally established to guarantee good outcomes in the treatment of chronic pain.  
In our study, although the necessity of a comprehensive approach was clear to many 
participants, they believed that there are not enough health centers that can provide such 
comprehensive service to patients with chronic pain. 
Family Health Teams (FHT) are primary health care organizations that include a team of 
family physicians, nurse practitioners, registered nurses, social workers, dietitians, and other 
professionals who work together to provide primary health care for their community (178). 
As discussed by two study participants, FHTs in Ontario have the potential to provide such 
multi-disciplinary services to patients, but this will necessitate higher financial supports 
from the government to implement provincially wide chronic pain services.  
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4. Patients concerns 
This study investigated concerns of patients as perceived by pharmacists. The main 
concerns identified were inadequate pain control, lack of emotional support and 
inadequate support by the government or health care providers. 
4.1 Inadequate pain control 
A four-year follow-up study reports that two third of patients do not receive adequate pain 
management (89). In another study, after 8 years follow-up, only 34.6% of patients were 
pain free (90).  
Inadequate pain management can be attributed in part to the unknown etiology of chronic 
pain. Study participants of the current study pointed out the fear of addiction, the lack of 
multi-disciplinary approaches, and lack of insurance coverage for some treatment options 
as reasons accounting for inadequate pain management. These findings are supported by a 
body of literature indicating inappropriate pain management by physicians, lack of 
multidisciplinary approach for pain management, fear of addiction to opioids and lack of 
coverage of treatment expenses by insurance as reasons for inadequate pain control (179). 
Uncontrolled pain, triggers a cascade of adversities to patients. Long lasting uncontrollable 
pain makes patients anxious, and affects their sleep, their ability to concentrate, their ability 
to work and their functionality. Debilitating uncontrollable chronic pain reduces income, 
which results in reduced ability to pay for treatment and medication expenses.  
4.2 Lack of support 
Findings of this study show that along with uncontrolled distressing pain, patients suffer 
from lack of support which can be another source of distress to patients with chronic pain. 
The support was categorized as support by family members and support by the government 
or health care system. Since pain is a subjective feeling, suffering of pain may not be 
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understood by other people. This places patients in an emotional state, in which the patient 
feels a need to be listened to and accredited. Literature shows that support by family and 
society can influence pain processing at the subjective–behavioral level as well as in the 
central nervous system level which may shield patients from the effect of pain distress (180-
182). The influence of social support on chronic pain, stress, and anxiety highlights the 
importance of cognitive behavioral therapy along with educating family members about the 
nature of chronic pain and the role of their support in patient experience of pain.  
The other sort of support is attributed to the shortage of facilities and lack of coverage for 
chronic pain treatments. As discussed by two participants, patients stay in long waiting lists 
to visit a pain specialist, lasting as long as two years, and multidisciplinary approaches for 
pain management are inadequate. This denies patients having access to ample health 
services that can improve their experience of pain and recover their functionality.  
5. Communication with prescribers  
Collaboration between health care providers is a requirement for better chronic pain 
management. Effective collaboration is based on good communication between health 
professions. Pharmacist participants were of the opinion that they had good communications 
with physicians, despite some obstacles. These barriers include: physicians are not 
accessible and occasionally, some physicians are not receptive to pharmacists’ comments. 
Some study participants stipulated that this is associated with the age, presence of a 
collaborative setting in the medical school they graduated from, previous experience 
working with pharmacists and their personality. Reportedly, physicians are unaware of the 
training and activities of community pharmacists and pharmacists feel that physicians have 
no appreciation of their role in health care (183-185). It is articulated that trustworthiness, 
role specification, and relationship initiation, identification of a more efficient way to deliver 
recommendations, and development of an appropriate compensation mechanism are 
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positively associated with pharmacist-physician collaboration (184-186), which are similar 
to current study findings.  
In our study, although participant pharmacists believed that they had good communication 
with physicians, they did not comment on whether this communication led to better 
collaboration with physicians toward improved patient care or not. When they mentioned 
errors in prescriptions, typos and legal issue of prescriptions as main reasons for 
communicating with prescribers, it appears that they mostly interpreted their 
communications with physicians for routine administrative work as the basis for a good 
relationship rather than collaborative communication with physicians for patient care.  
6. Knowledge gaps 
By having adequate knowledge about pain management, pharmacists can help patients to 
cope better with their pain and associated health difficulties. Up-to-date knowledge is a 
cornerstone of pain management, enabling pharmacists to offer better recommendations to 
physicians and patients. Most participants believed that they need more training in chronic 
pain management. The demand for training among our participants can be classified in three 
main categories: Knowledge about chronic pain, legal issues about opioids, and 
communication skills. Participants believe that since community pharmacists graduated 
from different schools and in different years, they have different levels or outdated 
knowledge about chronic pain management that can to lead to disparate recommendations 
to patients and inappropriate pain management. Pharmacist participants were of the opinion 
that this incongruity produces a lack of trust of pharmacists. However, they believe that this 
knowledge gap can be filled by short-term continuous educational programs such as 
workshops or webinars. Some participants also commented that they need more education 
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about legal issues concerning opioids, particularly on how to react to forgery and report 
misconduct to the authorities. 
Some of our pharmacist participants were of the opinion that pharmacists need to learn skills 
for effective communication, especially when they are engaged in several duties in their 
daily practice. 
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Conclusion                                                                                                                          
The current research study was primarily geared to exploring the experience of pharmacists 
in providing care to patients with chronic pain in the community setting. Expansions in 
pharmacists’ scope of practice and the emergence of pharmaceutical care have changed the 
role of pharmacists, moving from medication-oriented dispensing role toward a patient-
centered model of practice which pharmacists use their medication-related knowledge to 
assist patients. However, pharmacists are at early stages of this transition and still a lot to 
improve. To make patient care service better, understanding the current experience of 
pharmacists from patient care is critical. This experience can address gaps and deficiencies 
in providing care to patients.  Little research has focused on pharmacists’ experience 
providing care to patients with chronic pain in community setting. This study is a step to 
discern, describe and document the experience of pharmacists in every day practice. By this 
means it enhances our knowledge about pharmacists’ care of patients with chronic pain. 
This qualitative study describes the practice experiences of 9 pharmacists from community 
settings in Ontario who provide care to patients with chronic pain. Five major themes 
formed the basis of the outcomes: perception of chronic pain, opioids, patients concerns, 
communication with prescribers, and knowledge gaps. Pharmacists described challenges 
and concerns regarding chronic pain care based on their knowledge and experience. The 
most important concern all participants agreed upon, was misuse of opioids. They 
emphasized patient monitoring, appropriate utilization of medications and treatments to 
limit the potential of misuse of opioids. In caring for patients with chronic pain, study 
pharmacists felt these patients suffered not only from pain, but also suffered from not being 
seen, heard and understood by the society. From the perspective of participant pharmacists, 
patients with chronic pain do not get adequate support from the health care system. The 
Ontario government tried to control the increasing rates of opioid misuse and opioid-related 
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deaths by employing strategies such as discontinuing specific opioid products or not paying 
for high strength opioids, which can disproportionately impact patients with chronic pain. 
As experienced in case of oxycodone removal from the market in 2012, to reduce the amount 
of opioid overdose deaths, while oxycodone-related deaths decreased, the overall opioid 
fatalities increased. This conveys a message that governments need to reconsider the 
strategies to reducing opioid misuse. Rather than just simply removing a product from the 
market, policy makers may need to consider a more comprehensive and systematic 
approaches to regulate opioids use by patients and lessen opioid misuse and related deaths. 
Our study participants emphasize on the role of patient education, appropriate utilization of 
therapies through a comprehensive team approach, healthcare funding of non-opioid 
treatment of chronic pain and better patient monitoring as practical systematic tactics to 
improve chronic pain management and lessen the rate of opioid misuse and deaths.  
As gatekeepers, pharmacists can play a substantial role in patient education and patient 
monitoring to decrease misuse of opioids. However, bearing in mind the work load of 
pharmacists and time consuming procedure of patient education and monitoring, there 
should be motives such as incentives to encourage pharmacists to perform these tasks 
efficiently.  
Further research by means of focused group studies or mixed methods with participation of 
pharmacist, physicians and decision makers to investigate applicable forms of pharmacists’ 
collaboration in educating and monitoring of patients on opioids is recommended.  
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Appendices 
1. Pharmacists’ demographic data questionnaire 
Gender 
Volume at pharmacy 
………………………. Rx/day 
………………………. N/A Age 
Level Of education 
 BSc. in Pharmacy 
 Entry-Level Pharm.D 
 Post-Baccalaureate  
 Pharm.D 
 Residency trained 
 Fellowship trained 
 Other- please specify 
Practice years 
 < 5 years 
 5 - 10 years 
 11 - 15 years 
 16 - 20 years 
 > 20 years 
Geographical location 
 
 Rural (< 10,000) 
 Small urban (10,000 - 100,000) 
 Medium urban (100,001 - 250,000) 
 Large urban (250,001 - 750,000) 
 Metropolitan (> 750,000) 
Working setup  
 Community pharmacy 
 Independent pharmacy 
 Banner pharmacy 
 Franchise pharmacy 
 
 Chain pharmacy 
 Grocery/Department store 
 Family health team/Community health center 
 Other ………………………. 
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2. Pharmacist interview guide 
Chronic Pain Management (CPM) Semi-Structured Interview Guide  
Pharmacist interview guide 
- Introduction, reiterate data collection method (audio equipment)/use and security. 
- Opportunity for clarification 
Thank you to participate in this study “Pharmacists experience with chronic pain management: A 
qualitative study.” To start: 
Introductory 
1-a 
Please tell me about yourself. (For example, how long have you been 
working as a pharmacist…) 
1-b 
What is your understanding of chronic pain? For example, how do you 
define it? 
1-c 
Approximately, what percentages of your patients have chronic pain 
disorders? 
(e.g. Headache, low back pain, diabetic neuropathy, etc.) 
Feelings 2 
Generally speaking, how do you feel when you are approached by patients 
with chronic pain disorders? (what is different with other patients if any) 
- Asking for OTC (over the counter medications that do not need 
prescription) 
- Have a prescription for pain (including opioid medications) 
Concerns of 
patients about 
pain and opioids 
3 
In your experience, what are the main concerns of patients with chronic 
pain? 
pain intensity (disability), difficulty in communication with health 
providers, medications, perception of other people) 
 - How do you address these concerns? 
Opioids 
4-a 
What are your concerns about dispensing opioids? (for example, 
intoxication safety, adverse effects, dependence and addiction) 
-How do you address these concerns with patients and prescribers? 
4-b 
How do you respond when you are approached by an opioid seeking 
patient? 
(what is your reaction) 
4-c 
What concerns have patients expressed about use of opioids? (For 
example, stigma, cost, addiction, side effects) 
4-d 
Do you see resistance to use or over use for opioids in your patients? 
- How do you discuss these issues with patients? 
- Are you aware about tools that guides these discussions? 
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Communication 
5-a 
What is your experience with communicating your recommendations to 
the prescribers? 
- In your opinion, how effectively can a pharmacist with other health 
professionals (prescribers) in improving patients with chronic pain? 
- How do you communicate with prescribers or other health professionals 
about your patients with chronic pain? 
- How does a prescriber communicate with you about their concerns 
related to their chronic pain patients? 
- What concerns are usually discussed with other health professionals 
about patients with chronic pain? 
(for example: about prescribers’ opioid prescribing practices, safety issue 
(type of opioids), efficacy, legal or financial issues) (coverage) 
- What are the barriers to communicating your concerns with prescribers? 
(Prescriber is difficult to reach, not receptive, they do not communicate the 
treatment plan) 
- How do you feel (what is your experience) about communication with 
prescribers in this concern? 
5-b 
5-c 
When do you refer patients to other health care professionals? 
 - How do you refer patients to other health care professionals? 
Challenges 
6-a 
What are the main (complexities) in dealing with/ dispensing a prescription 
for patients with chronic pain? 
- In comparison to other patients, what barriers do you encounter in 
patients with chronic pain? 
(for example, fear of dispensing opioids, safety and legal issues) 
- In comparison to other patients, what differences do you encounter in 
patients with chronic pain?  
6-b 
In your opinion, to what extent can you help patients with chronic pain 
improve (relieve) their pain? In your opinion, what role should pharmacists 
play in helping patients with chronic pain? 
Education 
7-a 
In your opinion, do pharmacists need (more) training regarding chronic 
pain in order to fully address patients’ needs? 
- What kind of training do you think you would need? 
 (e.g. scientific issues [knowledge, patient assessment], communication 
skills, legal issues, pharmacy practice model) 
- Why? 
7-b 
Do you think (What are your ideas about) the educational material (in 
theory and practice) that are (were) taught in school about chronic pain, 
can address the skills required for the practice of chronic pain 
management? 
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7-c 
What are your suggestions for improving (advance) pharmacists’ skill 
(proficiency) in providing (dealing with) chronic pain management? 
- In school 
- In practice 
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3. Invitation poster 
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4. Invitation letter for pharmacists 
Email Script for Invitation 
Pharmacist experience with providing care for patients with chronic pain in the community 
setting: A qualitative study 
Dear (pharmacist),    
Our profession is evolving and we want to hear from you!  
We are a team of pharmacy practice researchers at the University of Waterloo School of Pharmacy. 
We are very interested in learning about your experiences with patients who have chronic pain, 
issues you may have encountered with opioid prescriptions, and interactions you’ve had with 
prescribers and other healthcare professionals. We are contacting you to invite you to participate 
in a study called Pharmacists’ experience with chronic pain management. The study aims to explore 
the perceptions, expectations and experiences of pharmacists who assist their patients manage 
chronic pain. We hope to use information from this study to inform the care provided by a 
pharmacist to patients with chronic pain.  
We are contacting you because you indicated your willingness to be contacted for future studies 
by providing your name and contact details when participated in one of our previous studies, titled, 
“Chronic Pain Management by Pharmacists Providing Care in the Community Setting in Ontario”.  
The principle investigators for this study were Dr. Feng Chang and Dr. Tejal Patel. 
If you agree to participate, a study researcher will interview you at a place and time of mutual 
convenience. The interview will take about an hour and be audio recorded for accuracy. The 
interviewer will ask you about your perceptions and experience with patients who have chronic 
pain, legal and other issues you may have encountered with opioid prescriptions, and your role in 
providing care to patients with chronic pain. The interview will be semi-structured so you will not 
be limited in your responses. Before the interview is over you will be provided with a summary of 
the key ideas you presented along with an opportunity to refine your thoughts and provide 
clarifications. 
If you are interested in participating or have any questions about the study, please contact Hamed 
Tabeefar (Pharm.D, MSc Candidate), School of Pharmacy, University of Waterloo, at 
htabeefar@uwaterloo.ca  or telephone: (519)-888-4567 x21371.     
We would like to assure you that all information obtained in the study will be kept confidential. 
This study has been reviewed by, and received ethics clearance through a University of Waterloo 
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Research Ethics Committee and any publications resulting from the study will use only de-identified 
data. 
Sincerely, 
Hamed Tabeefar, PharmD, MSc Candidate 
University of Waterloo School of Pharmacy 
Email: htabeefar@uwaterloo.ca 
Tel #: (519) 888-4567 x 21371 
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5. Information letter for pharmacist participants 
Project: Pharmacists' experience with chronic pain management: A qualitative study 
Study investigators: Dr. Feng Chang and Dr. Tejal Patel and Hamed Tabeefar 
INFORMATION LETTER  
Date: 
Dear Potential Participant: 
We are a team of pharmacy practice researchers at the University of Waterloo’s School of 
Pharmacy. We are very interested in learning about your experiences with patients who have 
chronic pain, issues you may have encountered with opioid prescriptions, and interactions you’ve 
had with prescribers and other healthcare professionals 
We would like to invite you to share your experience about patients with chronic pain with us in a 
study we are conducting titled as “Pharmacists experience with chronic pain management: A 
qualitative study”. This study is being led by Feng Chang (Pharm.D), Tejal Patel (Pharm.D) and 
Hamed Tabeefar (MSc Candidate) as part of Hamed’s MSc thesis, at the University of Waterloo, 
School of Pharmacy. We invite you to participate in a semi-structured interview. The objective of 
the study is to explore pharmacists’ perception and their experience with chronic pain 
management service. 
Procedures:  
Participation in this study is voluntary. If you agree to participate, we would like to have a semi-
structured interview with you. The interview will take place at a time and location of mutual 
convenience. The interview will take about 60 minutes of your time. With your permission, the 
interview will be audio recorded to facilitate collection of information, and later transcribed for 
analysis. The interviewer will ask questions about your perception and experience about patients 
with chronic pain in your practice; legal issues about opioid prescriptions, your self-perceived role 
in the treatment of patients with chronic pain; and closely related supporting questions. No direct 
identifiers will be collected for this study, but only brief demographic questions about level of 
education, geographical location (urban/rural), working set-up (independent pharmacy, 
branded/chain pharmacy or family health team) will be asked in our interview. You may decline to 
answer any of the interview questions if you so wish.  Further, you may decide to withdraw from 
this study at any time without any negative consequences by advising the researcher. Before the 
interview is over, you will be given a brief summary of key ideas presented during the interview, in 
order to allow for any final clarifications. All information you provide is considered completely 
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confidential. Your name will not appear in any thesis or report resulting from this study; however, 
with your permission, anonymous quotations may be used. Data collected during this study will be 
retained for 7 years in a locked office in my supervisor's office. Only researchers associated with 
this project will have access.  
If you have any questions regarding this study, or would like additional information to assist you in 
reaching a decision about participation, please contact me on (519)-888-4567 Ext. 21371) or by 
email at htabeefar@uwaterloo.ca. You can also contact my supervisors, Dr. Feng Chang on (519)-
888-4567 Ext. 21321 or email at feng.chang@uwaterloo.ca and Dr. Tejal Patel on (519)-888-4567 
Ext. 21337 or email at t5patel@uwaterloo.ca.                
Your participation is voluntary. Participation in this study is voluntary. You may decide to withdraw 
from this study at any time by advising the researcher, without any consequences.  
Possible risks or discomfort: There are no known or anticipated risks from participating in the semi-
structured interview session.  
Possible benefits: There are no direct benefits for the study of participants attending these 
interviews. As a pharmacist, your views and experiences are extremely valuable in helping 
pharmacist researchers understand your perception and experience in chronic pain management. 
Eligibility requirements for participation: All participants must be licensed community pharmacist, 
who presents chronic pain management in previously approved study “An Evaluation of the Effect 
of Community-based Pharmacist Intervention on Patients with Chronic Pain”.    
Confidentiality and data retention: All information you provide will be considered confidential. No 
direct identifiers will be collected for this study, but only brief demographic information about level 
of education, geographical location (urban/rural), working set up (independent pharmacy, 
branded/chain pharmacy or family health team) will be collected in our interview with your 
permission. The interviews will be audio-recorded to ensure accurate data transcription and 
analysis. No name or direct identifier of demographic data will be included in reports or 
publications; data will be coded using an alphanumeric system – no names will be included. Data 
collected during this study will be encrypted and retained for seven years in a secure location at 
our research offices at the University of Waterloo’s School of Pharmacy in Kitchener, Ontario.  
Remuneration. No monetary payment will be provided for participation in this study. 
Ethics review and clearance. I would like to assure you that this study has been reviewed and has 
received ethics clearance through a University of Waterloo Research Ethics Committee. However, 
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the final decision about participation is yours. If you have any comments or concerns resulting from 
your participation in this study, please contact Dr. Maureen Nummelin in the Office of Research 
Ethics at 1-519-888-4567, Ext. 36005 or maureen.nummelin@uwaterloo.ca. 
I very much look forward to speaking with you and thank you in advance for your assistance in this 
project. 
Yours Faithfully, 
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6. Consent form   
By signing this consent form, you are not waiving your legal rights or releasing the investigator(s) 
or involved institution from their legal and professional responsibilities. 
I have read the information presented in the information letter about a study being conducted by 
Dr. Feng Chang, Dr. Tejal Patel and Hamed Tabeefar (MSc candidate) from the School of Pharmacy 
at the University of Waterloo. I have had the opportunity to ask any questions related to this study, 
to receive satisfactory answers to my questions, and any additional details I wanted. 
I am aware that I have the option of allowing the interview to be audio recorded to ensure an 
accurate recording of my responses, and that audio-recording will not begin until I have consented. 
I am also aware that excerpts from the interview may be included in any reports and/or 
publications to come from this research, with the understanding that the quotations will be 
anonymous.  
I was informed that I may withdraw my consent at any time without penalty by advising the 
researcher.   
This project has been reviewed and received ethics clearance through a University of Waterloo 
Research Ethics Committee. If you have any comments or concerns resulting from your 
participation in this study.  I was informed that if I have any comments or concerns resulting from 
my participation in this study, I may contact the Director, Office of Research Ethics at 519-888-4567 
ext. 36005. 
With full knowledge of all foregoing, I agree, of my own free will, to participate in this study. 
YES     NO     
I agree to the audio recording of the interview discussion. 
YES    NO     
I agree to the use of anonymous quotations in any report and/or publication that comes of this 
research. 
YES     NO     
 
Participant Name: ____________________________________________ (Please print)   
Participant Signature: _________________________________________  
Date: __________________ 
